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A B S T R A C T
Background
Vitamins and minerals have many functions in the nervous system which are important for brain health. It has been suggested that
various different vitamin andmineral supplementsmight be useful inmaintaining cognitive function and delaying the onset of dementia.
In this review, we sought to examine the evidence for this in people who already had mild cognitive impairment (MCI).
Objectives
To evaluate the effects of vitamin and mineral supplementation on cognitive function and the incidence of dementia in people with
mild cognitive impairment.
Search methods
We searchedALOIS, theCochrane Dementia and Cognitive Improvement Group’s (CDCIG) specialised register, as well asMEDLINE,
Embase, PsycINFO, CENTRAL, CINAHL, LILACs, Web of Science Core Collection, ClinicalTrials.gov, and the WHO Portal/
ICTRP, from inception to 25 January 2018.
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Selection criteria
We included randomised or quasi-randomised, placebo-controlled trials which evaluated orally administered vitamin or mineral sup-
plements in participants with a diagnosis of mild cognitive impairment and which assessed the incidence of dementia or cognitive
outcomes, or both. We were interested in studies applicable to the general population of older people and therefore excluded studies in
which participants had severe vitamin or mineral deficiencies.
Data collection and analysis
We sought data on our primary outcomes of dementia incidence and overall cognitive function and on secondary outcomes of episodic
memory, executive function, speed of processing, quality of life, functional performance, clinical global impression, adverse events, and
mortality. We conducted data collection and analysis according to standard Cochrane systematic review methods. We assessed the risk
of bias of included studies using the Cochrane ’Risk of bias’ assessment tool. We grouped vitamins and minerals according to their
putative mechanism of action and, where we considered it to be clinically appropriate, we pooled data using random-effects methods.
We used GRADE methods to assess the overall quality of evidence for each comparison and outcome.
Main results
We includedfive trialswith 879participantswhich investigatedB vitamin supplements. In four trials, the interventionwas a combination
of vitamins B6, B12, and folic acid; in one, it was folic acid only. Doses varied. We considered there to be some risks of performance
and attrition bias and of selective outcome reporting among these trials. Our primary efficacy outcomes were the incidence of dementia
and scores on measures of overall cognitive function. None of the trials reported the incidence of dementia and the evidence on overall
cognitive function was of very low-quality. There was probably little or no effect of B vitamins taken for six to 24 months on episodic
memory, executive function, speed of processing, or quality of life. The evidence on our other secondary clinical outcomes, including
harms, was very sparse or very low-quality. There was evidence from one study that there may be a slower rate of brain atrophy over two
years in participants taking B vitamins. The same study reported subgroup analyses based on the level of serum homocysteine (tHcy)
at baseline and found evidence that B vitamins may improve episodic memory in those with tHcy above the median at baseline.
We included one trial (n = 516) of vitamin E supplementation. Vitamin E was given as 1000 IU of alpha-tocopherol twice daily. We
considered this trial to be at risk of attrition and selective reporting bias. There was probably no effect of vitamin E on the probability
of progression from MCI to Alzheimer’s dementia over three years (HR 1.02; 95% CI 0.74 to 1.41; n = 516; 1 study, moderate-
quality evidence). There was also no evidence of an effect at intermediate time points. The available data did not allow us to conduct
analyses, but the authors reported no significant effect of three years of supplementation with vitamin E on overall cognitive function,
episodic memory, speed of processing, clinical global impression, functional performance, adverse events, or mortality (five deaths in
each group). We considered this to be low-quality evidence.
We included one trial (n = 256) of combined vitamin E and vitamin C supplementation and one trial (n = 26) of supplementation
with chromium picolinate. In both cases, there was a single eligible cognitive outcome, but we considered the evidence to be very low-
quality and so could not be sure of any effects.
Authors’ conclusions
The evidence on vitamin and mineral supplements as treatments for MCI is very limited. Three years of treatment with high-dose
vitamin E probably does not reduce the risk of progression to dementia, but we have no data on this outcome for other supplements.
Only B vitamins have been assessed in more than one RCT. There is no evidence for beneficial effects on cognition of supplementation
with B vitamins for six to 24 months. Evidence from a single study of a reduced rate of brain atrophy in participants taking vitamin B
and a beneficial effect of vitamin B on episodic memory in those with higher tHcy at baseline warrants attempted replication.
P L A I N L A N G U A G E S U M M A R Y
Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive
impairment
Review question
This review investigated whether people with mild cognitive impairment can reduce their risk of developing dementia, or can prevent
their memory or other thinking skills from deteriorating further, by taking vitamin or mineral supplements.
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Background
Slight changes in memory and thinking skills are common as people get older. When these changes are worse than can be expected
in normal ageing, but are not bad enough to make a person’s usual activities difficult to manage, then the person is said to have mild
cognitive impairment (MCI). People with MCI are at increased risk of developing dementia in the future.
Vitamins and minerals are naturally occurring substances which are needed in the diet to maintain health. They have lots of different
functions in the body and many are essential to keep the brain working properly. It has been suggested that supplementing a person’s
normal diet with extra doses of these vitamins or minerals might help to maintain thinking skills or prevent dementia.
Study characteristics
We found eight randomised controlled trials (RCTs), which investigated four different types of vitamin or mineral pills by comparing
them to a placebo (a dummy pill). The vitamins tested were B vitamins (vitamin B6, vitamin B12 and folic acid), vitamin E, and
vitamin E and C given together. The only mineral tested was chromium.
Key results and quality of the evidence
Vitamin B combination versus placebo
Five trials with a total of 879 participants compared B vitamins with placebo. Four used combinations of vitamin B6, vitamin B12, and
folic acid; one small study tested folic acid on its own. None of these studies reported whether or not participants developed dementia.
These studies did not find that memory or thinking skills differed between the group of people who took vitamin B supplements
and those who took placebo after treatment lasting six months to two years. Our confidence in the results on different tests used in
the studies varied from moderate to very low. Two years of vitamin B supplements did seem to help memory in a small subgroup of
participants in one study who could be identified by a particular blood test at the start of the trial. One study found that there was
probably no effect on participants’ quality of life. One study scanned the brains of some participants and reported that B vitamins may
slow the rate of brain shrinkage.
Harmful effects and deaths were reported in very few participants and we cannot conclude whether or not there are harms from taking
these or similar combinations of B vitamins.
Vitamin E versus placebo.
One study with 516 participants compared a relatively high dose of vitamin E (2000 IU a day) to placebo in people who were also taking
a multivitamin containing 15 IU of vitamin E (the daily requirement for vitamin E is approximately 30 IU). The risk of developing
dementia due to Alzheimer’s disease (the commonest form of dementia) is probably not affected by three years of treatment with high-
dose vitamin E. The quality of the evidence for other outcomes was lower, but there may also be no effect of this dose of vitamin E on
specific memory or thinking skills or on how well people could manage their daily activities.
Vitamin E and C versus placebo
One study with 256 participants compared a combination of vitamins C and E with placebo. It found no effect on overall memory
and thinking skills, but we had little confidence in this result because of the quality of the evidence.
Chromium picolinate versus placebo
Only one very small study with 26 participants investigated the effect of chromium supplements. This study was too small for us to be
able to draw any conclusions.
Conclusions
The amount and quality of research evidence about vitamin and mineral supplements for treating MCI in people without nutritional
deficiency is limited. At the moment, it is not possible to identify any supplements which can reduce the risk of people with MCI
developing dementia or which can effectively treat their symptoms. More research is needed before we can answer our review question.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
B vitamins compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: B vitamins (B6, B12, folic acid)
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) of participants
(studies)
Certainty of the evidence
(GRADE)
Comments
Risk with placebo Risk with B vitamins
Incidence of dementia - not
measured
- - - -
Overall cognit ive funct ion
assessed with: MMSE
Scale f rom: 0 to 30
follow-up: range 6 months
to 24 months
MD with B vitamins was 0.44 MMSE points higher
(0.23 lower to 1.12 higher) than with placebo *
488
(3 RCTs)
⊕©©©
VERY LOW 123
Due to the very low-quality
of the evidence, we cannot
be sure of any ef fect of B vi-
tamins on overall cognit ive
funct ion
* 2 studies reported f i-
nal score; 1 study reported
change f rom baseline. From
the 2 studies (n=150) which
reported f inal scores, the
mean MMSE with placebo
was 26.97 points
Episodic memory
assessed with: various
word list recall instruments
a
f ollow-up: range 6 months
to 24 months
SMD with B vitamins was 0.09 higher
(0.1 lower to 0.29 higher) than with placebo
397
(3 RCTs)
⊕⊕⊕©
MODERATE 3
B vitamins probably re-
sulted in lit t le to no dif fer-
ence in episodic memory
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Execut ive funct ion
assessed with: various in-
strumentsb
f ollow-up: range 6 months
to 24 months
SMD with B vitamins was 0.03 higher
(0.23 lower to 0.29 higher) than with placebo
392
(3 RCTs)
⊕⊕⊕©
MODERATE 4
B vitamins probably re-
sulted in lit t le to no dif fer-
ence in execut ive funct ion
Speed of processing
assessed with: various in-
strumentsc
f ollow-up: range 6 months
to 24 months
SMD with B vitamins was 0.04 higher
(0.26 lower to 0.34 higher) than with placebo
173
(2 RCTs)
⊕⊕⊕©
MODERATE 4
B vitamins probably re-
sulted in lit t le to no dif fer-
ence in speed of processing
Quality of lif e
assessed with: D-QOL
Scale f rom: 1 to 5
follow-up: 12 months
The mean quality of lif e was
3.5 points
MD 0 points
(0.1 lower to 0.1 higher)
138
(1 RCT)
⊕⊕⊕©
MODERATE 5
B vitamins probably re-
sulted in lit t le to no dif fer-
ence in quality of lif e
Mortality - not reported Reported by only one study (2/ 133 died in vitamin B group,
0/ 133 died in placebo group)
- -
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
MD: Mean dif ference; SMD: Standardised mean dif ference; CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to risk of bias. One study was at high risk of performance bias and at unclear risk of select ion and detect ion
bias.
2 Downgraded due to inconsistency. I2 = 87%.
3 Downgraded due to imprecision. 95%CI included lit t le or no ef fect and small benef it of B vitamins.
4 Downgraded due to imprecision. 95%CI included small ef fects in either direct ion.
5 Downgraded due to imprecision. Result derived f rom one small study.5
V
ita
m
in
a
n
d
m
in
e
ra
l
su
p
p
le
m
e
n
ta
tio
n
fo
r
p
re
v
e
n
tin
g
d
e
m
e
n
tia
o
r
d
e
la
y
in
g
c
o
g
n
itiv
e
d
e
c
lin
e
in
p
e
o
p
le
w
ith
m
ild
c
o
g
n
itiv
e
im
p
a
irm
e
n
t
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
aEpisodic memory assessed with Hopkins Verbal Learning Test, word learning and the Auditory Verbal Learning Test.
bExecut ive funct ion assessed with CLOX, the Stroop test, and the Frontal Assessment Battery.
cSpeed of processing assessed with Trail-making Test A, digit cancellat ion, and the Digit-Symbol Subst itut ion Test.
CLOX:Clockdrawingexecutivetest
D-QOL: Dementia quality of lif e quest ionnaire
MCI :Mildcognitiveimpairment
MMSE: Mini-mental state examinat ion
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Mild cognitive impairment and dementia
Prior to the onset of dementia, there can be a prodromal (pre-
symptomatic) stage which is often termed ’mild cognitive impair-
ment’ (MCI). The category of MCI captures those individuals
whose cognitive deficits are beyond those typically seen in normal
ageing and who are at high risk of future dementia. Different cri-
teria have been proposed to identify MCI, but, broadly speaking,
MCI of the amnestic subtype is a state where individuals have
subjective and objective memory impairment that is inconsistent
with age, but normal global cognitive functioning, and normal
performance in non-memory cognitive domains. The main focus
of these criteria is to detect memory problems due to prodromal
Alzheimer’s disease (AD). However, not all forms of MCI evolve
into ADdementia and, therefore, there have been calls for broader,
more inclusive criteria. In 2003, an International Working Group
(IWG) developed consensus criteria and expanded the definition
of MCI to include objective and subjective impairments in any
cognitive domain (Winblad 2004). The influential Petersen crite-
ria have been similarly extended (Petersen 2004). In recent years,
new criteria have been proposed for MCI due to AD, including
the National Institute on Aging-Alzheimer’s Association (NIA-
AA) criteria for preclinical/prodromal states (Albert 2011), up-
dated NIA-AA research criteria (Jack 2018), and updated versions
of the IWG criteria (Dubois 2014).
Dementia is a syndrome of cognitive and functional decline which
is usually progressive and which involves impairment inmore than
one cognitive function, memory being the most commonly af-
fected in the early stages. Other higher cortical functions such as
orientation, comprehension, learning, language, and judgement
are also often affected. In most cases, the onset of dementia and
its subsequent progression is gradual. The cognitive deficits in the
early stages of the illness are relatively mild, but still have an im-
pact on the ability to perform some normal daily activities. As the
syndrome progresses, people with dementia eventually become in-
creasingly dependent on others for support with all activities of
daily living.
Types of MCI and dementia
There are numerous different definitions of MCI, with different
focus (e.g. nature of the neuropsychological impairment, such as
memory or non-memory (Matthews 2007); prevalence (Stephan
2007); and risk of progression to dementia (Matthews 2008). Fur-
ther subdivisions can be made depending on the suspected under-
lying cause of the cognitive deficits (e.g.MCI due to AD andMCI
due to vascular disease, termed ’vascular cognitive impairment no
dementia’ (VCIND)). Moreover, attempts have been made to de-
velop new criteria to capture even earlier preclinical states includ-
ing, for example, ’pre-MCI’ that captures individuals with im-
paired executive function and language, higher apathy scores, and
lower left hippocampal volumes on brain imaging compared to
normal controls (Duara 2011). There is no standard definition of
MCI universally accepted for use in clinical trials (Stephan 2013),
but adaptations of the criteria suggested by Petersen are commonly
used (Petersen 1999).
Subtypes of dementia are distinguished by the underlying pathol-
ogy. The four most common subtypes are Alzheimer’s disease de-
mentia (AD) (accounting for an estimated 60% to 70% of all de-
mentia cases); vascular dementia (VaD); dementia with LewyBod-
ies (DLB); and frontotemporal dementia (FTD). Accurate diagno-
sis of the subtypes may be difficult. Mixed pathology is common,
with more than 80% of cases having some features of Alzheimer’s
disease (Jellinger 2006; WHO 2012). However, the proportion
of dementia attributable to Alzheimer’s disease reduces with age
(Savva 2009).
Prevalence of MCI and dementia
In the UK Medical Research Council’s population-based Cogni-
tive Function and Ageing Study (CFAS), when 18 different defini-
tions of MCI were mapped, the range of prevalence estimates was
found to be highly variable (0.1% to 42.0%), and conversion rates
to dementia generally low (Stephan 2007). In general, prevalence
and conversion rates in specialist settings have been reported to be
higher than in population-based studies (adjusted conversion rate
from MCI to dementia 9.6% versus 4.9%) (Mitchell 2009).
The risk of dementia increases with age; according to a World
Health Organization (WHO) report, only 2% to 10% of cases
start before the age of 65 (WHO 2012). The same report esti-
mated that there were 35.6 million people with dementia in the
world in 2010, and that this figure would double every 20 years
to reach 65.7 million in 2030 (WHO 2012). However, there is a
degree of uncertainty about the expected increase in prevalence of
dementia. Recent research in the UK (Matthews 2013) and Den-
mark (Christensen 2013) suggests that the age-specific prevalence
of dementia may be falling in developed countries, supporting
the idea that there may be modifiable risk factors. Nevertheless,
because of population ageing, the overall prevalence continues to
rise.
Risk factors
Generally, risk factors for dementia can be divided into modi-
fiable and non-modifiable factors. The non-modifiable risk fac-
tors include age, genetic factors, family history, gender (females
are at higher risk), and Down syndrome. The modifiable factors
are smoking, high cholesterol, stroke, hypertension, lack of phys-
ical activity, diabetes mellitus, obesity, and low educational level.
Among the non-modifiable risk factors, age has the greatest effect.
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It has been calculated that in people older than 65, the risk of
AD (the commonest cause of dementia) doubles every five years
(Launer 1999;McCullagh 2001; van den Berg 2012; van der Flier
2005). A pooled analysis of four prospective studies in Europe
found the incidence rate of AD among people aged 90 and over to
be 63.5/1000 person-years (Launer 1999). Genetics plays a major
role in early onset AD, but a lesser role in the much commoner
late onset disease. Epidemiological evidence suggests that many of
the modifiable risk factors (diabetes, midlife obesity, midlife hy-
pertension, smoking, and physical inactivity) are risk factors for
both AD and vascular disease, including vascular dementia (The
World Alzheimer Report 2014; WHO 2012).
At present, there is no cure for any subtype of dementia, but identi-
fying and targeting modifiable risk factors may offer opportunities
to modify its onset and course. Research has been reported sug-
gesting that cognitive stimulation, exercise, diet, and the manage-
ment of vascular risk factors such as hypertension, diabetes, obe-
sity, smoking, and physical inactivity may have an important role
in prevention of AD (Lindsay 2002; Lourida 2013; Norton 2014;
Wilson 2002). There is also some evidence in support of vitamin
supplementation as a preventive strategy. For example, vitamin
B12 and folate lower levels of homocysteine, which is believed to
be toxic to neurones. Protective effects of vitamin D and vitamin
E against AD have also been proposed (Annweiler 2012; Dysken
2014; Llewellyn 2010). Many minerals might have antioxidant
properties and may also be beneficial in protecting against oxida-
tive stress and free radical damage. Hence, an evaluation of the
role of vitamins and minerals as protective and preventive agents
in cognitive impairment is warranted (see Appendix 1).
Description of the intervention
This review focusses on RCTs investigating the effect of vitamin
and mineral supplementation for preventing dementia or delay-
ing cognitive decline in people with mild cognitive impairment.
Vitamins are organic compounds that are essential for the nor-
mal physiological process in the body and play important roles in
growth and development (Kennedy 2011). Minerals are inorganic
elements that come from the earth; as nutrients, they have similar
essential roles in normal physiology (Centers for Disease Control
and Prevention 2014). All of these essential nutrients are available
naturally in food, although deficiencies can occur due to inade-
quate dietary intake or a variety of disease states. Dietary supple-
ments are any consumed products that aim to provide additional
nutrients to those obtained from the usual diet.
How the intervention might work
Vitamins and minerals have multiple important roles in the phys-
iology of the human body at cellular and tissue levels. Putative bi-
ological mechanisms for each are summarised briefly in Appendix
1.
There is a complex array of micronutrients which protect the brain
in a variety of ways, including protection against damaging oxy-
gen-free radicals, and which are important in neurogenesis, gene
expression, and enzyme and receptor control (Powell 2000). Fail-
ure of these important systems appears to be implicated in the
occurrence of neural damage (van der Schaft 2013). Therefore,
ensuring adequate vitamin and mineral levels in the body might
enhance cognitive function.
Oxidative stress has been shown to be a damaging process lead-
ing to an imbalance between oxygen-free radicals, and the anti-
oxidative defences and repair of oxidative damage to proteins,
lipids, RNA, and DNA (Halliwell 1992; Halliwell 1999; Tabet
2001; Tabet 2002). In addition, the central nervous system (CNS)
contains high levels of unsaturated fatty acids that are substrates
for peroxidation reactions (Ogawa 1994). An important defence
mechanism in the brain involves enzymatic antioxidants which,
if mediated through the supplementation of micronutrients, may
replenish the brain with synthetic antioxidants providing a thera-
peutic approach to reduce oxidative stress (Reiter 1995). This may
be a useful adjunct in modifying risk factors in the pathogenesis
of neurodegenerative disorders (Packer 1997).
Vitamins:
Vitamins have a wide range of roles in the central nervous system
and hence may affect the pathophysiological processes underlying
the dementias in numerous different ways. Vitamin A may be
involved in the stabilisation of beta amyloid fibrils (Ono 2012).
Vitamin D is a precursor of hormones required for calcium and
phosphorusmetabolism and also has a possible role in cognition in
older adults (Przybelski 2007). Vitamin E is an antioxidant which
provides protection against free radical damage (Farina 2012;
Takatsu 2009). B vitamins, particularly vitaminB12 and folic acid,
have a role in energy production and metabolism within the CNS.
B vitamins have also been implicated in the production of nucleic
acids andproduction andmaintenance ofmyelin essential for good
neuronal health (Kühnast 2013; Osiezagha 2013; Pawlak 2014;
Powers 2003; The World Alzheimer Report 2014). See Appendix
1 for more detail of possible mechanisms.
Minerals:
Minerals, similarly, have a very wide range of functions. For ex-
ample, some may be involved in neuronal gene expression and
the secretion of neurotransmitters (Ozawa 2012; Rossom 2012).
Potassium, calcium, and magnesium were reported to be protec-
tive against cognitive decline in a cohort of Japanese participants
(Ozawa 2012). Selenium is a critical component of the enzyme
glutathione peroxidase and has been shown to protect the CNS
and immune system from oxidative damage by harmful free rad-
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icals (Berr 2012; Mehdi 2013; Smorgon 2004). See Appendix 1
for more detail of possible mechanisms.
Micronutrients may not be maximally effective if supplemented in
isolation. There are some patented formulas consisting of complex
mixtures of micronutrients which are claimed to work synergis-
tically. These are sometimes marketed as licensed medical foods.
These licensedmedical foods are not covered in this set of reviews.
Why it is important to do this review
The prevalence and financial implications of dementia are such
that small effects on cognitive decline or on the incidence of de-
mentia may have a large impact on healthcare costs and the overall
burden of dementia. Robust assessments are needed of the effect
size of interventions and of the ‘dose’ and duration of intervention
necessary to achieve an effect.
For individuals, fear of cognitive decline and dementia may be a
powerful motivator to seek preventive interventions. Nutritional
supplements and cognitive activities (e.g. computerised ’brain
training’ games), in particular, are subject to promotion by those
with commercial interests. It is important for people to know
whether time, effort, and money they might invest to prevent cog-
nitive decline is likely to be well spent. Information about adverse
effects is also important. Although nutritional and behavioural in-
terventions are often perceived to be ‘low risk’, they are not nec-
essarily without the potential to cause harm. For example, trials
have found high doses of vitamin E to be associated with more ad-
verse effects than placebo (Bjelakovic 2012; Brigelius-Flohe 2007;
Miller 2005).
People with MCI are interested in interventions which could pre-
vent or delay further cognitive decline. In addition, this review
will be of interest to clinicians providing care for people with MCI
and to policy makers.
O B J E C T I V E S
To evaluate the effects of vitamin andmineral supplementation on
cognitive function and the incidence of dementia in people with
mild cognitive impairment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included in the review randomised or quasi-randomised con-
trolled trials, published or unpublished, reported in any language.
We included studies involving both randomised and non-ran-
domised trial arms, but we only considered results from the for-
mer. We included cross-over studies, but extracted and analysed
data from the first treatment period only.
Types of participants
We included the following population: people diagnosed with
mild cognitive impairment (MCI) according to internationally
accepted and validated criteria. We recorded definitions. Partici-
pants should have been reported to be free of dementia at base-
line. Consequently, we included only trials which assessed cogni-
tive function or dementia status with internationally accepted and
validated instruments at baseline and follow-up.
We excluded trials of participants with severe vitamin or mineral
deficiency where the intervention given could correct these defi-
ciencies.
Types of interventions
We included studies comparing the effects of the described vita-
min andmineral supplements with control interventions that were
not expected to have specific risk-modifying effects. The control
arms typically involved placebo or no intervention/usual care. The
minimum treatment duration was set at 12 weeks. Experimen-
tal interventions could be single vitamin or mineral supplements
or combination treatments with any of the supplements listed in
Appendix 1. We excluded trials of vitamins or minerals given in
combination with other unrelated compounds (e.g. amino acids,
fatty acids, or medications) unless the effects of the vitamins and
minerals could be isolated. For example, a trial evaluating the ef-
fects of vitamin A and C versus methionine would have been ex-
cluded, whereas a trial evaluating vitamin A and C with methio-
nine versus methionine only would have been included. We in-
cluded only orally-administered supplements. There were no re-
strictions on dose.
Types of outcome measures
Primary outcomes
1. The incidence of all-cause dementia (assessed using internation-
ally accepted and validated criteria).
Themain time point of interest was end of trial, defined as the time
point with the longest follow-up duration as measured from ran-
domisation (see also section, Data extraction and management).
Outcome data reported at other time points after randomisation
were extracted and presented. For this outcome, the minimum
follow-up period was 12 months.
2. Overall cognitive functioning, measured with, for example,
Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-
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cog); the Mini Mental State Examination (MMSE); Repeat-
able Battery for the Assessment of Neuropsychological Status
(RBANS); Cambridge Cognition Examination (CAMCOG).
Secondary outcomes
Secondary outcomes were any internationally accepted and vali-
dated measures of:
- specific cognitive functioning subdomain: episodic memory,
- specific cognitive functioning subdomain: executive functioning,
- specific cognitive functioning subdomain: speed of processing,
- quality of life, either generic or disease-specific,
- clinical global impression,
- functional performance,
- number of participants experiencing one or more serious adverse
events (SAE),
- mortality.
- biomarkers: where studies included validated biomarkers (e.g.,
beta-amyloid or tau in cerebrospinal fluid, structural MRI or amy-
loid imaging) as well as cognitive outcomes, biomarker data were
extracted.
Outcomes included in the ’Summary of findings’ table
Critical effectiveness outcomes included in the ’Summary of find-
ings’ table for this review were incidence of dementia, all outcomes
related to cognitive functioning, quality of life, and mortality.
Search methods for identification of studies
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois), the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) specialised register on 25 January 2018.
ALOIS is maintained by the Information Specialists for the CD-
CIG, and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy elderly populations. The studies are iden-
tified through:
1. Monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO and
LILACS;
2. Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials, and the Netherlands National Trials Register, plus
others);
3. Quarterly search of the Cochrane Library’s Central Register
of Controlled Trials (CENTRAL);
4. Six-monthly searches of a number of grey literature sources:
ISI Web of Science Core Collection; Index to Theses;
Australasian Digital Theses.
To view a list of all sources searched for ALOIS, see ’About ALOIS’
on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement, and cognitive enhancement trials, can be viewed in
the ‘methods used in reviews’ section within the editorial informa-
tion about the Cochrane Dementia and Cognitive Improvement
Group.
We ran additional searches in MEDLINE, Embase, PsycINFO,
CENTRAL, CINAHL,Web of Science Core Collection, LILACs,
ClinicalTrials.gov, and the WHO Portal/ICTRP to ensure that
the searches for each suite of reviews was as comprehensive and
as up-to-date as possible to identify published, unpublished, and
ongoing trials. The search strategies used for the retrieval of reports
of trials can be seen in Appendix 2.
Searching other resources
We screened reference lists of all included trials. In addition, we
screened reference lists of recent systematic reviews, health tech-
nology assessment reports, and subject-specific guidelines identi-
fied throughwww.guideline.gov. The searchwas restricted to those
guidelines meeting the 2013 inclusion criteria of the National
Guideline Centre (NGC), published in this year or later.
We contacted experts in the field and companies marketing in-
cluded interventions, in order to provide additional randomised
trial reports that were not identified by the search.
Data collection and analysis
We used this protocol, alongside instructions for data extraction,
quality assessment, and statistical analyses which were based on a
generic protocol generated by the editorial board of CDCIG to
guide this and another 11 reviews on modifiable risk factors (see
Acknowledgements).
Selection of studies
If multiple reports described the same trial, we included all to
allow complete extraction of the trial details.
We used crowdsourcing to screen the search results. Details of this
method have been described here (http://www.medicine.ox.ac.uk/
alois/content/modifiable-risk-factors). In brief, teams of volun-
teers performed a ‘first assess’ on the search results. The volun-
teers were recruited through the author team’s institutions. They
screened the results using an online tool developed for Cochrane
Embase project but tailored for this programme of work. The
crowd decided, based on a reading of title and abstract, whether the
citation was describing a randomised or quasi-randomised trial,
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irrespective of the citations topic. The citations identified as possi-
bly relevant by the crowd were then screened by the author team.
Data extraction and management
Two review authors, working independently, extracted trial infor-
mation using a standardised and piloted extraction method, re-
ferring also to a guidance document. Discrepancies were resolved
by discussion, or by the involvement of a third reviewer. Where
possible, we extracted (as a minimum) the following information
related to characteristics of participants, intervention, and study
design:
Participant characteristics
• gender
• baseline age (range, median, mean)
• education (level and years of education)
• baseline cognitive function
• cognitive diagnostic status
• duration of cognitive symptoms, if any
• ethnicity
• Apo-E genotype
• diabetes mellitus (yes/no)
• physical activity (as defined by the trialists).
• smoking (never/ever)
Intervention characteristics
• nature of the intervention/generic and trade name of
intervention
• description of the control condition
• duration of treatment
• dosage and frequency
• any concomitant treatments
• treatment adherence
Methodological characteristics
• trial design (individual or cluster randomisation; parallel
group, factorial or cross-over design)
• number of participants
• outcome measures used
• duration of follow-up, as measured from randomisation
• duration of follow-up, as measured from end of treatment
• source of financial support
• publication status
If secondary outcome data were available at multiple time-points
within a given trial, we grouped them as follows: immediate (up
to 12 weeks), short-term (up to one year), medium-term (one
to two years) and longer-term results (more than two years). For
the primary outcome (all-cause dementia), we considered only
outcome data at one year of follow-up or longer. Within these
time periods, we extracted the latest available data reported by the
study. For example, if a study reported data at six months, nine
months and one year, we extracted and analysed only the one-year
data for the one-year (short-term) time point.
For dichotomous outcomes (such as incident dementia or mortal-
ity), we extracted from each trial the number of participants with
each outcome at each time point.
For continuous outcomes, we extracted the number of participants
in whom the outcome was measured, and the mean and standard
deviation of the change from baseline for each outcome at each
time point. If change-from-baseline data were not available, we
extracted the mean value at each time point. When necessary,
means and measures of dispersion were approximated from figures
in the reports.
Whenever possible, we extracted intention-to-treat data, i.e.
analysing all participants according to the group randomisation;
if this was not available, then we extracted and reported data from
available case analyses. If neither of these types of data were avail-
able, we considered data from ’per protocol’ analyses. We con-
tacted the trialists if we were unable to obtain the necessary data
from the trial report.
Assessment of risk of bias in included studies
After completion of a standardised training session provided by
AR, one member of the author team and one experienced reviewer
provided by the editorial team independently assessed the risk of
bias in each of the included trials using the Cochrane’s ’Risk of
bias’ tool (Higgins 2011). We resolved disagreements by consen-
sus. We assessed the risk of bias potentially introduced by subop-
timal design choices with respect to sequence generation, conceal-
ment of allocation, blinding of participants and caregivers, blinded
outcome assessment, selective outcome reporting, and incomplete
outcome data, including the type of statistical analyses used (true
intention-to-treat versus other analyses). The general definitions
that were used are reported in the Cochrane Handbook for System-
atic Reviews of Interventions (Higgins 2011).
Measures of treatment effect
We expressed the measure of treatment effect for continuous out-
comes as a mean difference if all included studies used the same
outcome measure and as a standardised mean difference (SMD),
defined as the between-group difference in mean values divided
by the pooled standard deviation (SD), if the same outcome was
assessed with a variety of measurement scales. We expressed the
treatment effect for dichotomous outcomes as a relative risk (RR).
Unit of analysis issues
We did not identify any cross-over or cluster-randomised trials for
inclusion.
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Dealing with missing data
Missing data in individual trials may put the study estimates of
effects at a high risk of bias, and may lower the overall quality of
the evidence according to GRADE (Higgins 2011).We dealt with
missing data in our ’Risk of bias’ assessments and evaluated attri-
tion bias in stratified analyses of the primary outcomes (Appendix
2). We analysed the available information and did not contact au-
thors with a request to provide missing information; nor did we
impute missing data ourselves.
Assessment of heterogeneity
We examined heterogeneity in stratified analyses by trial, partici-
pant, and intervention characteristics, as outlined in the sections
Data and analyses and Appendix 2.
Assessment of reporting biases
We identified too few trials to allow the use of funnel plots to
explore reporting biases or other small study effects.
Data synthesis
We examined participants, interventions, and outcomes in the
included trials in order to decide whether they were sufficiently
similar for data to be pooled.
Where we considered it appropriate to pool data, we used standard
inverse-variance random-effects meta-analysis to combine out-
come data across the trials at the end of trials (DerSimonian 1986);
and, if possible, at least one additional time point (see Primary
outcomes and Data extraction and management for definitions of
time points). We visually inspected forest plots for the presence
of heterogeneity and calculated the variance estimate tau² as a
measure of between-trial heterogeneity (DerSimonian 1986). We
prespecifed a Tau² of 0.04 to represent low heterogeneity, 0.09 to
represent moderate heterogeneity, and 0.16 to represent high het-
erogeneity between trials (Spiegelhalter 2004). We also presented
the I² statistic and the corresponding Chi² test (Higgins 2003).
I² describes the percentage of variation across trials attributable to
heterogeneity rather than to chance, with values of 25%, 50%,
and 75% typically being interpreted as low, moderate, and high
between-trial heterogeneity. We preferred Tau² over I² in the in-
terpretation of between-trial heterogeneity, as the interpretation of
I² can be largely affected by the precision of trials included in the
meta-analysis (Rücker 2008).We did statistical analyses in Review
Manager 5 (RevMan 2014) and in STATA, release 13 (StataCorp,
College Station, Texas).
Subgroup analysis and investigation of heterogeneity
We had prespecified the following trial characteristics as of interest
for exploring possible heterogeneity: concealment of allocation,
blinding of participants, blinded outcome assessment, intention-
to-treat analysis, trial size ( based on power calculation for trial pri-
mary outcome), duration of treatment ( <3, 3-12, >12 months),
and length of follow-up from randomisation ( <3 months, 3-12
months, >1-2 years, >2 years).We had also prespecified the follow-
ing possible clinical effect modifiers: age ( 40-65 or >65 years), co-
morbidities, concomittant medications, and ethnicity ( Dawson-
Hughes 2004). However, too few studies were included to allow
us to conduct subgroup analyses or explore the effect of these fea-
tures. Because B vitamins may work by lowering homocysteine
levels and thereforemay bemore effective in participants with high
homocysteine levels at baseline, we decided to amend the protocol
to report the effects of B vitamins in subgroups of participants
distinguished by level of homocysteine at baseline, where this was
reported in the included studies (see Differences between protocol
and review).
Sensitivity analysis
We had prespecified a sensitivity analysis for the primary effec-
tiveness outcome, including high-quality trials only. However, too
few trials were included for this to be done.
GRADE and summary of findings table
We used GRADE to describe the quality of the overall body of
evidence for each outcome in the ’Summary of findings’ table
(Higgins 2011; Guyatt 2008).
Quality in GRADE is defined as the degree of confidence which
can be placed in the estimates of treatment benefits and harms.
There are four possible ratings: ’high’, ’moderate’, ’low’ and ’very
low’. Rating evidence as ’high-quality’ implies that we are con-
fident in our estimate of the effect, and further research is very
unlikely to change this. A rating of ’very-low’ quality implies that
we are very uncertain about the obtained summary estimate of the
effect.
The GRADE approach rates evidence from RCTs which do not
have serious limitations as ’high-quality’. However, several factors
can lead to the downgrading of the evidence to ’moderate’, ’low’
or ’very low’. The degree of downgrading is determined by the se-
riousness of these factors: study limitations (risk of bias); inconsis-
tency; indirectness of evidence; imprecision; and publication bias
(Higgins 2011; Guyatt 2008; Chandra 2001).
R E S U L T S
Description of studies
Results of the search
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We conducted searches in December 2014, July 2015, March
2016, August 2016, March 2017, and January 2018. In total, we
retrieved 7,257 records from the six searches. After de-duplica-
tion, 5211 records remained. A Crowd and the CDCIG infor-
mation specialist assessed these at title and abstract level. In total,
725 results remained after this assessment. The review team then
screened these records. Of these, we assessed 110 full-text arti-
cles describing 67 trials for eligibility and included eight trials in
the review (one after the authors provided subgroup data). Three
trials, one described in three papers, were placed in the section
’Awaiting classification’; we sought information from the authors
of these trials but received none. We identified one ongoing study
of vitamin D supplementation which was due to be completed in
July 2018. This process is depicted in Figure 1.
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Figure 1. Study flow diagram.
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Included studies
We identified eight studies eligible for inclusion in this review. For
full details see Characteristics of included studies.
We grouped the studies into four comparisons. Five studies com-
pared B vitamins to placebo (de Jager 2012, Eussen 2006, Fan
2017, Ting 2017, van Uffelen 2008). One study compared vita-
min E to placebo (Petersen 2005), one compared vitamin E + vi-
tamin C to placebo (Naeini 2014), and one compared chromium
picolinate to placebo (Krikorian 2010).
Appendix 3 shows the supplement doses used in the studies in
relation to the mean daily intake from food and the recommended
daily intake for adults in the UK.
Comparison 1: B vitamins versus placebo - description of
studies
Five studies with 879 randomised participants contributed data to
this comparison.
Setting
The studies were conducted in the UK, the Netherlands (2 stud-
ies), China and Singapore. Eussen 2006 included participants liv-
ing in the community or in a care home; participants in all other
studies were resident in the community.
Participants
All studies specifically excluded participants with dementia. de
Jager 2012, Fan 2017 and van Uffelen 2008 used broadly similar
criteria for MCI, which included a memory complaint and scores
within a specified range on scales of cognition and daily function-
ing. Participants in Eussen 2006 had a Clinical Dementia Rat-
ing (CDR) global score of 0 or 0.5; for this review we, used data
from the participants with a CDR score of 0.5. All participants
in Ting 2017 had recent lacunar stroke and cognitive impairment
- no dementia (CIND); the cognitive impairment was defined as
scoring at least 1.5 SDs below expected in at least one domain of
a neuropsychological test battery.
All participants in Eussen 2006 met the authors’ criteria for mild
B12 deficiency.
Four studies had age-based inclusion criteria: de Jager 2012 and
Eussen 2006 only included participants aged 70 or older, Fan 2017
only included participants aged 60 to 75 years, and van Uffelen
2008 included participants aged 70 to 80 years. Across all studies,
the mean age of participants ranged from approximately 66 years
(Fan 2017) to approximately 80 years (Eussen 2006).
Interventions
All studies were placebo-controlled. The experimental interven-
tions varied in composition and dose.
• Participants in de Jager 2012 received 0.5 mg B12 + 0.8 mg
folic acid + 20 mg B6 once daily for two years.
• Eussen 2006 was a three-arm study. For this review, we
combined the groups receiving 1 mg B12 and 1 mg B12 + 0.4
mg folic acid into a single experimental intervention group.
Treatment was once daily for 24 weeks.
• Participants in Fan 2017 received 0.4 mg folic acid once
daily for six months.
• Participants in Ting 2017 received 0.5 mg B12 + 2 mg folic
acid + 25 mg B6 once daily for one to five years.
• Participants in van Uffelen 2008 received 0.4 mg vitamin
B12 + 5 mg folic acid + 50 mg vitamin B6 once daily for a year.
This study also investigated the effect of aerobic exercise in a 2 x
2 factorial design. For the purposes of this review, we combined
data for all participants receiving vitamin B supplementation or
placebo (i.e. with or without aerobic exercise) into single
experimental and control groups.
Outcomes
None of the studies reported on our primary outcome of incidence
of all-cause dementia (although diagnosis of dementia by DSM-
IV was listed as a secondary outcome in the protocol for de Jager
2012).
Four of the five studies measured overall cognitive function with
the MMSE (de Jager 2012, Fan 2017, Ting 2017, van Uffelen
2008).
We were able to extract data on episodic memory from three stud-
ies, which assessed delayed recall on the Hopkins Verbal Learning
Test (de Jager 2012), word learning (Eussen 2006) and the Audi-
tory Verbal Learning Test (van Uffelen 2008). We extracted data
on executive function from four studies, which used CLOX (de
Jager 2012), the Stroop test (Eussen 2006; van Uffelen 2008) and
the Frontal Assessment Battery (Ting 2017). We extracted data
on speed of processing from three studies, which used Trail-mak-
ing Test A (Eussen 2006), digit cancellation (Ting 2017), and the
Digit-Symbol Substitution Test (van Uffelen 2008).
Only van Uffelen 2008 reported on quality of life, using the de-
mentia-specific D-QOL scale.
de Jager 2012 reported overall clinical impression using global
CDR scores.
Fan 2017 reported functional performance on a 14-item Chinese
ADL scale.
de Jager 2012 reported efficacy results separately for participants
with high or low total homocysteine (tHCy) (based on themedian
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values at baseline). However, it was possible to calculate results
for the whole experimental intervention and control groups from
the reported means and standard deviations. van Uffelen 2008
reported results for men and women separately in each group, but
some of the outcomes were reported in enough detail to allow us
to combine the data for men and women.
Data on adverse events were reported by de Jager 2012 and van
Uffelen 2008.
Comparison 2: Vitamin E versus placebo - description of
study
One study with 769 participants investigated this comparison (
Petersen 2005). The study also had a donepezil arm. The primary
outcome of the study was time to development of possible or
probable Alzheimer’s disease.
Setting
The study took place at 69 Alzheimer’s Disease Cooperative Study
(ADCS) sites in the US and Canada.
Participants
Participants were aged 55 to 90 years and had amnestic MCI of
a degenerative nature (insidious onset and gradual progression).
Specific cognition-related inclusion criteria were impaired mem-
ory, a logical memory delayed-recall score approximately 1.5 to 2
SD below an education-adjusted norm and a score of 24 to 30 on
the MMSE, as well as a CDR global score of 0.5.
Intervention
The experimental group of interest to this review received 2000
IU vitamin E (1000 IU twice daily), placebo donepezil, and a
multivitamin (containing 15 IU of vitamin E) for three years. The
comparator group received placebo vitamin E, placebo donepezil
and the same multivitamin. Any participant who met clinical cri-
teria for Alzheimer’s disease at any time in the study was offered
open-label donepezil until study completion.
Outcomes
The study assessed progression to possible or probable Alzheimer’s
disease. Overall cognitive function was assessed with the MMSE
and with a composite score derived from a battery of individual
neuropsychological tests. Composite scores of interest to this re-
view were also derived for the domains of memory and executive
function (and additional composites for language and visuospa-
tial function). Clinical global impression was assessed using the
Global Deterioration Scale (GDS) and the CDR. Functional per-
formance was assessed using the ADCS Mild Cognitive Impair-
ment ADL Scale. Data on individual adverse events were reported
by treatment group if they occurred in at least 5% of subjects in the
donepezil or vitamin E group and at least two times in the placebo
group during the double-blind phase. The number of deaths in
each treatment group was also reported.
Comparison 3: Vitamin E + vitamin C versus placebo -
description of study
One study investigated this comparison (Naeini 2014). It reported
data on the 256 participants who completed the study (out of 296
who were randomised).
Setting
The study took place at a single centre in Iran with participants
recruited from community clubs for retired people.
Participants
Dementia was listed as an exclusion criterion, but there was no
information on how this was applied. Participants were defined as
having MCI and identified as eligible for inclusion on the basis
of a score of 21 to 26 on the validated Iranian version of the
MMSE. We considered this not to be an adequate definition of
MCI. However, we decided to include the study, downgrading the
result for indirectness in relation to our review question.
Intervention
The experimental intervention was 300 mg vitamin E (DL-alpha-
tocopherol) + 400 mg vitamin C once daily for one year. The
comparator was placebo.
Outcome
The only outcome of interest to this review was overall cognitive
functioning assessed with the MMSE.
Comparison 4: Chromium picolinate versus placebo -
description of study
One small study with 26 participants contributed data to this
comparison (Krikorian 2010).
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Setting
This single centre study recruited participants via community ad-
vertisement.
Participants
Participants had a global rating of 0.5 on the CDR.
Intervention
The experimental intervention was chromium picolinate contain-
ing 1000 mcg elemental chromium once daily for 12 weeks. The
comparator was placebo.
Outcome
The only outcome of interest to this review was episodic memory
assessed with the California Verbal Learning Test (CVLT).
Excluded studies
The Characteristics of excluded studies table shows the reasons for
exclusion of 55 studies which were assessed in full text. The most
common reasons for exclusion were the wrong population (par-
ticipants did not have MCI) or the wrong intervention (included
additional components or was given for less than 12 weeks).
Three studies are awaiting classification. In all three cases, we have
been unable to obtain additional information from the authors at
the time of writing. No results were available from one study. Re-
sults from the other two trials have been published, but we consid-
ered that essential information on various details of the methods,
sample sizes, or results was missing.
We identified one ongoing trial of vitamin D supplementation
which, according to the trial register, was due to be completed in
July 2018.
Risk of bias in included studies
We describe the risk of bias of the included studies in the table,
Characteristics of included studies. Our ’Risk of bias’ judgments
are also depicted in the ’Risk of bias’ summary and ’Risk of bias’
graph (Figure 2 and Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Three studies (de Jager 2012, Petersen 2005, Ting 2017) provided
enough information to judge the risk of selection bias to be low.
The remaining five studies provided insufficient information on
randomisation methods so we judged them to be at unclear risk
of selection bias.
Blinding
Fan 2017 was an open-label study which we judged to have a
high risk of performance bias and an unclear risk of detection
bias. There was also a lack of information about blinding from
Krikorian 2010 and Naeini 2014. The other studies were at low
risk of bias in this domain.
Incomplete outcome data
The longer studies - Petersen 2005 and Ting 2017 - lost high
numbers of participants to follow-up and we considered them to
be at high risk of attrition bias by the end of the study. We judged
the risk of attrition bias in Naeini 2014 to be unclear due to a lack
of information on the group allocation of those who dropped out.
The risk was also unclear in Krikorian 2010, where there was no
information about whether or not there were any missing data.
The remaining studies were at low risk of bias in this domain.
Selective reporting
We judged there to be a high risk of reporting bias in two studies.
de Jager 2012 mentioned a number of outcomes in the protocol,
including some relevant to this review, which were not reported.
Petersen 2005 reported composite z-scores rather than individual
test results and did not report the number of participants in each
analysis. Ting 2017 may have selected only some cognitive results
from a larger neuropsychological test battery; we judged its risk
of reporting bias to be unclear. We judged the risk in the other
studies to be low, although for some studies there was no protocol
and this judgement was based on the outcomes mentioned in the
Methods sections of the papers being fully reported.
Other potential sources of bias
We found no other obvious sources of bias and rated this risk as
low for all studies.
Effects of interventions
See: Summary of findings for the main comparison B vitamins
compared to placebo for MCI; Summary of findings 2 Vitamin
E compared to placebo forMCI; Summary of findings 3Vitamin
E + vitamin C compared to placebo for MCI
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Comparison 1: B vitamins (folic acid, B12, B6) versus
placebo
Five studies contributed data to this comparison (de Jager 2012;
Eussen 2006; Fan 2017; Ting 2017; van Uffelen 2008).
Ting 2017 differed significantly from the other studies in recruit-
ing only participants who had a recent history of lacunar stroke
and in following them up for up to five years. In our primary
analyses, in order to maximise comparability with the other stud-
ies, we included data from the one-year outcome point from Ting
2017, but we considered the population as a potential source of
heterogeneity. We also reported the results of this study at later
time points, although these were all associated with substantial
loss of participants from follow-up.
de Jager 2012 reported the data for participants with higher (above
median) baseline total homocysteine (tHcy) and lower baseline
total homocysteine levels separately. For the primary analyses,
we combined these groups. However, we also reported and com-
mented on their subgroup data.
van Uffelen 2008 reported results separately for men and women;
we have combined these datawherewe incorporated them inmeta-
analyses.
Primary outcomes
Incidence of all-cause dementia
No study reported the incidence of all-cause dementia.
Overall cognitive functioning
Four studies used the MMSE to assess overall cognitive function-
ing (de Jager 2012; Fan 2017; Ting 2017; van Uffelen 2008).
It is unknown what would constitute an important difference in
MMSE score in this population. It is unlikely thatMMSE is sensi-
tive to small changes in cognition in people with MCI. We pooled
data from three studies which reported MMSE in the form of
mean score with standard deviation in each treatment group.
van Uffelen 2008 presented MMSE results as medians with in-
terquartile ranges (IQR) for men and women separately. After 12
months of treatment, themedian (IQR)MMSE score among men
was 28 (27 to 30) in the vitamin group and 29 (28 to 29) in the
placebo group. For women, the median (IQR) MMSE score was
identical in both vitamin and placebo groups: 29 (27 to 30).
The pooled analysis of MMSE scores from the other three stud-
ies after six to 24 months was inconclusive due to imprecision;
although the result slightly favoured B vitamins, we could not ex-
clude the possibility of there being little or no effect (MD 0.44,
95%CI -0.23 to 1.12, 3 studies, 488 participants; Analysis 1.1,
Figure 4). There was high heterogeneity in this analysis (I2 = 87%).
This appeared to be due to a beneficial effect of B vitamins on
MMSE score in Fan 2017, which was the only open-label (un-
blinded) study. We considered the evidence behind this result to
be very low-quality because of the imprecision, study limitations,
and inconsistency.
Figure 4. Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.1 Overall cognitive function
(MMSE).
de Jager 2012 reported the data separately for participants with
higher and lower baseline total homocysteine (tHcy). The results
in these subgroups were also imprecise: higher baseline tHcy (MD
0.70, 95% CI -0.16 to 1.56; participants = 111); lower baseline
tHcy (MD -0.30, 95% CI -1.10 to 0.50; participants = 112).
Ting 2017 did not find any significant effect of B vitamins on
MMSE at any later time point (up to five years).
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Secondary outcomes
Specific cognitive functioning subdomain: episodic memory
We pooled data on episodic memory from three studies (de Jager
2012; Eussen 2006; van Uffelen 2008). All used tests which in-
volved delayed recall of word lists. There was probably little or
no effect of six to 24 months of B vitamin supplementation on
episodic memory (SMD 0.09, 95% CI -0.10 to 0.29; 3 studies,
397 participants; Analysis 1.2; Figure 5). Heterogeneity was low
(I2 = 0%). We considered this to be moderate-quality evidence,
downgraded due to imprecision.
Figure 5. Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.2 Episodic memory.
In de Jager 2012, there was better episodic memory after 24
months in the group treated with vitamin B than in the group
treated with placebo among participants with higher baseline
tHCy (MD 1.30, 95% CI 0.02 to 2.58; participants = 111), but
episodic memory did not differ significantly between intervention
groups among participants with lower baseline tHcy (MD -0.30,
95% CI -1.58 to 0.98; participants = 112). The authors had anal-
ysed this outcome by logistic regression at five time points, start-
ing from the 3rd month of the study, and estimated that after two
years of the vitamin B intervention, participants taking vitamin
B had a 69% higher likelihood of correct word-recall than those
taking placebo (OR 1.69, P = 0.001) (de Jager 2012).
Specific cognitive functioning subdomain: executive
functioning
Four studies assessed executive functioning using three different
measures (de Jager 2012; Eussen 2006; Ting 2017; van Uffelen
2008). We used CLOX-1 data from the CLOX test and ’task
3’ from the Stroop Colour-Word Test. Ting 2017 reported only
change-from-baseline data, so we were unable to pool these with
data from the other studies. There was probably little or no effect
of six to 24 months of B vitamin supplementation on executive
functioning (SMD 0.03, 95% CI -0.23 to 0.29; 3 studies, 392
participants; Analysis 1.3; Figure 6). Heterogeneity was modest (I
2 = 30%). We considered this to be moderate-quality evidence,
downgraded due to imprecision. Ting 2017 reported no signifi-
cant difference between B vitamin and placebo groups on change
from baseline in the Frontal Assessment Battery at any time point
from one to five years.
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Figure 6. Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.3 Executive function.
From de Jager 2012, there was no evidence of a difference in
CLOX-1 score between intervention groups among participants
with either higher baseline tHcy (MD0.30, 95%CI -0.50 to 1.10;
participants = 111) or lower baseline tHCy (MD 0.50, 95% CI -
0.13 to 1.13, participants = 112).
Ting 2017 did not find any significant effect of B vitamins on
executive functioning at any later time point (up to five years).
Specific cognitive functioning subdomain: speed of
processing
Three studies assessed speed of processing using three different
measures (Eussen 2006; Ting 2017; van Uffelen 2008). Again,
we were unable to include data from Ting 2017 in the meta-
analysis because only change-from-baseline data were available.
There was probably little or no effect of six to 24 months of B
vitamin supplementation on speed of processing (SMD0.04, 95%
CI -0.26 to 0.34; 2 studies, 173 participants; Analysis 1.4; Figure
7). Heterogeneity was low (I2 = 0%). We considered this to be
moderate-quality evidence, downgraded due to imprecision. Ting
2017 reported no significant difference in change-from-baseline
of speed of processing (digit cancellation) between B vitamin and
placebo groups at any time point from one to five years.
Figure 7. Forest plot of comparison: 1 B vitamins versus placebo, outcome: 1.4 Speed of processing.
Ting 2017 did not find any significant effect of B vitamins on
speed of processing at any later time point (up to five years).
Quality of life, either generic or disease-specific
One study (van Uffelen 2008) reported dementia-specific quality
of life using D-QOL.There was no evidence of any effect of B
vitamins after one year (MD 0, 95% CI -0.1 to 0.1; 1 study, 138
participants; Analysis 1.5). We considered this to be moderate-
quality evidence, downgraded due to imprecision.
Clinical global impression
de Jager 2012 assessed overall clinical state using CDR. The au-
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thors reported that “(i)n the whole intention-to-treat cohort, there
was no significant effect of B vitamins on CDR (P = 0.23)”, nor
was there a significant interaction with baseline tHcy split by me-
dian. However, when they stratified tHcy by quartiles, they noted
a significant benefit of B vitamins on CDR in the quartile with
the highest tHcy at baseline (P = 0.039, Fisher’s exact test). In
this subgroup, they calculated that “the odds of having CDR=
0 at follow-up is five times greater in the active-treatment group
compared with placebo (P = 0.02).” It was not clear whether or
not this was a prespecified analysis.
Functional performance
One study (Fan 2017) assessed functional performance using a 14-
itemADLscale (range of possible scores 14 to 56,with a lower score
representing a better outcome). There may be a small beneficial
effect of B vitamins on functional performance after six months
(MD -0.78, 95% CI -1.35 to -0.21; 1 study, 75 participants;
Analysis 1.6). We considered this to be very low-quality evidence,
downgraded due to imprecision and very serious concern about
study limitations.
Number of participants experiencing one or more serious
adverse events (SAE)
Two papers reported adverse events. van Uffelen 2008 reported
minor adverse events in 3/179 randomised participants (2 in B
vitamins group, 1 in placebo group). de Jager 2012 reported 242
adverse events in total in the B vitamins group (n = 133) and 271
in the placebo group (n = 133) over two years.
Mortality
de Jager 2012 reported two deaths in the B vitamins group (2/133)
but none in the placebo group (0/133). No deaths were reported
by the other studies.
Biomarkers
de Jager 2012 reported the rate of brain atrophymeasured byMRI.
Out of 133 participants who started treatment in each group, 85
in the vitamin and 83 in the placebo group had serial MRI scans
which were technically suitable for analysis. After adjustment for
age, the rate of brain atrophy per year was reported to be 29.6%
lower in the active treatment group (0.76%, 95%CI 0.63 to 0.90)
than in the placebo group (1.08%, 95% CI 0.94 to 1.22) (P =
0.001).
Comparison 2: Vitamin E versus placebo
One study with 516 participants contributed data for this com-
parison (Petersen 2005).
Sample sizes for change scores were not reported for some out-
comes, making it impossible to re-analyse the data without impu-
tation of sample sizes. It was difficult to tell how the study had
treated the missing data arising from participants who discontin-
ued the study during the double-blind phase (reported as 72 in the
vitamin E group and 66 from the placebo group), and participants
who had developed Alzheimer’s Disease by 36 months and had
therefore been transferred to an open-label phase for treatment
with donepezil (76 participants in the vitamin E group and 73 in
the placebo group).
A z-scorewas calculated for cognitive domain scores. Positive num-
bers on this score indicated better outcomes.
Primary outcomes
Incidence of all-cause dementia
The study did not report the incidence of all-cause dementia, but
did report the incidence of Alzheimer’s dementia. By 12 months,
33 participants in the vitamin E group and 38 in the placebo
group had progressed to Alzheimer’s dementia. By 36 months,
these numbers were 76 and 73 respectively. There was no signifi-
cant difference between vitamin E and placebo groups in the prob-
ability of progression from MCI to Alzheimer’s dementia over 36
months based on Cox analysis (HR 1.02; 95% CI 0.74 to 1.41;
n = 516; 1 study) (Petersen 2005). There was also no significant
difference between groups at any of the six-monthly time points
between baseline and 36 months (prespecified analyses). We con-
sidered this to be moderate-quality evidence, downgraded due to
imprecision.
Overall cognitive functioning
This was measured usingMMSE and ADAS-Cog at a six-monthly
interval from baseline for three years. At 36 months, the change
from baseline in MMSE score (range 0 to 30, a higher score was
better) was -2.20 ± 3.64 in the vitamin E group and -2.75 ± 4.04
in the placebo group. This was reported not to be statistically
significant. We were not able to calculate the mean differences
since sample sizes were not reported. There was also reported to
be no significant difference in the change from baseline for ADAS
Cog (modified) score (range 0 to 85, a higher was worse); this was
3.98 ± 7.56 in the vitamin E group and 3.72 ± 8.54 in the placebo
group.We considered this to be low-quality evidence, downgraded
due to risk of bias and imprecision (single study, estimated sample
size).
Secondary outcomes
We considered the evidence on all of the secondary outcomes
reported here to be low-quality, downgraded due to risk of bias and
imprecision (single study, estimated sample size in each analysis).
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Specific cognitive functioning subdomain: episodic memory
The study reported the change from baseline in a standardised z-
score for a memory domain, incorporating ADAS-cog immedi-
ate and delayed word-recall scores and the New York University
immediate and delayed paragraph-recall scores. Positive numbers
indicated improvement. At 36 months, the change from baseline
was -0.31 ± 0.59 in the vitamin E group and -0.28 ± 0.62 in the
placebo group. This was reported not to be statistically significant.
Sample size was not reported.
Specific cognitive functioning subdomain: executive
functioning
The study reported the change from baseline in a standardised z-
score for an executive function domain, incorporating the Dig-
its-Backward test, Symbol Digit Modalities test, and Number-
Cancellation test. Positive numbers indicated improvement. At 36
months, the change from baseline was -0.19 ± 0.48 in the vitamin
E group and -0.19 ± 0.53 in the placebo group. This was reported
not to be statistically significant. Sample size was not reported.
Specific cognitive functioning subdomain: speed of
processing
Not reported in the study.
Quality of life, either generic or disease-specific
Not reported in the study.
Clinical global impression
The study reported the change in Global Deterioration Scale
(range 0 to 7, higher was worse) from baseline to 36 months (0.64
± 0.96 in the vitamin E group, 0.56 ± 0.99 in the placebo group).
The number of participants in the analysis was not reported. This
difference was described as not statistically significant in the study
report.
Functional performance
This was measured with the Activities of Daily Living Scale, which
can range from 0 to 53, with higher scores indicating better func-
tion. The change from baseline at 36 months was -5.63 ± 8.75 in
the vitamin E group and -6.39 ± 8.99 in the placebo group. The
sample sizes used to calculate these values were not reported. The
difference was described as not statistically significant.
Number of participants experiencing one or more serious
adverse events (SAE)
This was not reported in the study. There was no statistically sig-
nificant difference between vitamin E and placebo groups in the
rate of ten individual adverse events which were reported because
they occurred in at least 5% of participants receiving donepezil or
vitamin E and at least twice among participants receiving placebo.
Mortality
Five subjects died in each of the vitamin E (n = 257) and placebo
(n = 259) groups during the double-blind phase.
Other validated biomarkers
Not reported in the review.
Comparison 3: Vitamin E and C versus placebo
Only one study Naeini 2014 contributed to this comparison.
Primary outcomes
Incidence of all-cause dementia
Not assessed.
Overall cognitive functioning
This was measured using the Iranian version of the MMSE (val-
idated for the local population, range 0 to 30) after one year of
treatment. The mean and standard error of the mean at six and
12 months were reported. The difference between the groups was
described as not statistically significant at either time point.
We assumed that all participants described as completing the study
were analysed and estimated the mean difference at the end of the
study. This indicated that there may be no little or no effect of
supplementation with vitamins E and C (MD0.23, 95%CI -0.25
to 0.71; 1 study, 256 participants; Analysis 3.1).We considered
this to be very low-quality evidence, downgraded due to indirect-
ness (inadequate definition of MCI), risk of bias, and imprecision
(result from a single study).
Secondary outcomes
Mortality
There was one reported death, but the treatment allocation of this
person was not reported.
None of our other secondary outcomes were reported.
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Comparison 4: Chromium picolinate versus placebo
Only one study Krikorian 2010 contributed data to this compari-
son. This study was very small (n = 26). There were 15 participants
in the intervention arm and 11 in the placebo arm.
Primary outcomes
The incidence of all-cause dementia
Not assessed.
Overall cognitive functioning
Not assessed.
Secondary outcomes
Specific cognitive functioning subdomain: episodic memory
This was measured using the Californian Verbal Learning test (test
for episodic verbal learning and memory) at 12 weeks. Group
differences were not significant for performances on the CVLT
learning trials (46.8 versus 45.8; P = 0.72), short-delay recall (9.4
versus 8.4; P = 0.30), long-delay recall (9.3 versus 9.5; P = 0.78), or
recognition memory (14.4 versus 14.2; P = 0.77). We considered
this to be very low-quality evidence due to serious concern about
study limitations and very serious concern about imprecision.
None of our other secondary outcomes were reported.
25Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Vitamin E compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: vitamin E
Comparison: placebo
Outcomes Impact of participants
(studies)
Certainty of the evidence
(GRADE)
Incidence of dementia due to Alzheimer’s
disease
follow-up: 36 months
76 cases in vitamin E group and 73 cases
in placebo group (HR 1.02, 95% CI 0.74 to
1.41)
516
(1 RCT)
⊕⊕⊕©
MODERATE 1
Overall cognit ive funct ioning
assessed with: MMSE and ADAS-cog
follow-up: 36 months
Single study reported no signif icant dif -
ference between groups in changes f rom
baseline of MMSE or ADAS-cog. Sample
sizes not reported
(1 RCT) ⊕⊕©©
LOW 23
Episodic memory
assessed with: z-score incorporat ing vari-
ous instrumentsa
f ollow-up: 36 months
Single study reported no signif icant dif -
ference between groups. Sample size not
reported
(1 RCT) ⊕⊕©©
LOW 23
Execut ive funct ioning
assessed with: z-score incorporat ing vari-
ous instrumentsb
f ollow-up: 36 months
Single study reported no signif icant dif -
ference between groups. Sample size not
reported
(1 RCT) ⊕⊕©©
LOW 23
Quality of lif e - not measured - -
Mortality No signif icant dif f erence in deaths re-
ported between vitamin E, donepezil, and
placebo groups during double-blind phase
of trial
(1 RCT) -
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to imprecision. 95%CI around hazard rat io included possible ef fect in both direct ions.
2 Downgraded due to imprecision. Single study. Sample size for this outcome not reported.
3 Downgraded due to risk of bias. High risk of bias due to incomplete outcome data and select ive report ing.
aEpisodic memory assessed using standardised composite z-score incorporat ing ADAS immediate and delayed word-recall
scores and the New York University immediate and delayed paragraph-recall scores.
bExecut ive funct ion assessed using standardised composite z-score incorporat ing the digits-backward test, Symbol Digit
Modalit ies Test, and number-cancellat ion test.
ADAS−cog:Alzheimer ′sDiseaseAssessmentScale−cognitive
MCI: M ild cognit ive impairment
MMSE: Mini-mental state examinat ion
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Vitamin E + vitamin C compared to placebo for MCI
Patient or population: MCI
Setting: community
Intervention: vitamin E + vitamin C
Comparison: placebo
Outcomes Anticipated absolute effects∗ (95% CI) of participants
(studies)
Certainty of the evidence
(GRADE)
Comments
Risk with placebo Risk with vitamin E + vita-
min C
Incidence of dementia - not
measured
- - - -
Overall cognit ive funct ion
assessed with: MMSE (Ira-
nian version)
Scale f rom: 0 to 30
follow-up: 12 months
The mean overall cognit ive
funct ion was 26.6 points
MD 0.23 points higher
(0.25 lower to 0.71 higher)
256
(1 RCT)
⊕©©©
VERY LOW 123
Due to very low-quality evi-
dence, we cannot be sure of
any ef fect of vitamin C + vi-
tamin E on overall cognit ive
funct ion
Episodic memory - not mea-
sured
- - - -
Execut ive funct ion - not
measured
- - - -
Speed of processing - not
measured
- - - -
Quality of lif e - not mea-
sured
- - - -
Mortality - not reported - - - -
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Downgraded due to risk of bias. Unclear risks of select ion, performance, and attrit ion bias.
2 Downgraded due to indirectness. Inadequate def init ion of MCI.
3 Downgraded due to imprecision. Result f rom a single small study.
MCI :Mildcognitiveimpairment
MMSE: Mini-mental state examinat ion
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D I S C U S S I O N
Summary of main results
This review included eight RCTs which investigated the effect of
vitamin or mineral supplements on the incidence of dementia or
on cognitive function in participants with mild cognitive impair-
ment at baseline. Five studies with 879 randomised participants
investigated the effect of B vitamins; in four of these studies the
intervention was a mixture of vitamins B12, B6 and folic acid
and in one study it was folic acid only. The other supplements
included were vitamin E (one study, 769 participants), vitamins
E and C (one study, 256 participants) and chromium picolinate
(one study, 26 participants).
None of the included studies assessed the incidence of all-cause
dementia, one of our primary outcomes. One study found that
there was probably no effect of vitamin E on the probability of
progression fromMCI to dementia due to Alzheimer’s disease over
three years.
All of the studies reported on one or more measures of cognitive
function.
For B vitamins, we found very low-quality evidence on overall
cognitive function. There was probably little or no effect on any
of our specific cognitive subdomains of interest (episodic memory,
executive functioning, and speed of processing). Only one study
reported on each of global clinical impression and quality of life,
and there was no evidence of any effect. There was only very
low-quality evidence on functional performance from one small,
open-label study. The very few data available on adverse events
or mortality did not suggest any difference between groups. The
only study reporting biomarker data found a reduction in the
rate of brain atrophy over two years in the B vitamin group. We
added to our protocol the reporting of subgroup data by baseline
homocysteine (tHcy) level. The one study that reported such data
found that there may be a significant benefit of B vitamins on
episodic memory - but not overall cognitive function or executive
function - of participants with tHcy above the median at baseline.
The study of vitamin E did not provide the data we needed to con-
duct analyses. The authors reported no significant effect of vita-
min E supplementation on overall cognitive functioning, episodic
memory, executive functioning, clinical global impression, func-
tional performance, incidence of adverse events, or mortality.
The quality of evidence on vitamins E and C in combination
(effect on overall cognitive function) and on chromium picolinate
(effect on episodic memory) was very low so we had very little
confidence in the results.
Overall completeness and applicability of
evidence
The five trials all included community-dwelling participants aged
over 55 with mild cognitive impairment. In one of the studies of
B vitamins, participants all had mild B12 deficiency at baseline at
a level which is common in older people, but otherwise partici-
pants were not selected on the basis of nutritional status. Not all
studies assessed nutritional status at baseline, but participants in
all other studies had, or could be expected to have had, normal di-
etary intake for their population of origin and a low risk of specific
vitamin or mineral deficiencies. The results of this review do not
apply to people with significant nutritional deficiencies. In one
study, participants had vascular cognitive impairment after a re-
cent lacunar stroke; in the other studies, there was no selection for
cause of cognitive impairment. Overall, the participants seemed
to be quite well representative of people with MCI seen in clinical
practice. The range of vitamin and mineral supplements tested
was limited. Only B vitamins were investigated in more than one
study and these studies all used different dose combinations so
that it was not possible to isolate effects of individual B vitamins
or to assess dose-response relationships. The dose of folic acid used
in some studies was similar to the maximum dietary intake in the
UK population; doses of other vitamins were at least ten times
more than the reference nutrient intake (see Appendix 3). All trials
assessed different primary and secondary outcomes. Only one trial
assessed progression to dementia due to Alzheimer’s disease and
none assessed progression to all-cause dementia. Overall cognitive
function was assessed mainly with the MMSE which has limited
sensitivity to detect small changes in cognition in a population
with MCI. There were few data on quality of life, global impres-
sion, functional performance, or adverse events. Only one study
reported a biomarker outcomewhich has beenwidely used inMCI
populations, namely, the rate of atrophy on structural MRI.
Quality of the evidence
There was somemoderate-quality evidence relating to the effect of
B vitamins on specific cognitive domains and quality of life, and
the effect of vitamin E on incidence of Alzheimer’s dementia. The
remaining evidence was of low- or very low-quality. Some of the
more serious concerns about risk of bias related to performance
bias in one open-label study, attrition bias in two studies and
selective outcome reporting in two studies. For the comparisons of
the vitamin E and C combination and chromium picolinate with
placebo, the only evidence was of very low-quality because of study
limitations and very small sample sizes. The evidence concerning a
possible differential effect on episodicmemory in participants with
higher or lower baseline homocysteine levels came from subgroups
in a single study and must be regarded as preliminary.
Potential biases in the review process
We considered search biases to be unlikely.We used a standardised
search strategy to identify articles, including unpublished stud-
ies. These search methods included a single-concept search across
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multiple sources along with a search of the Cochrane trial reg-
ister. This sensitive search approach may have identified studies
that would have potentially been overlooked using less rigorous
search methods. However, we found too few studies to conduct
any formal tests to assess the likelihood of publication bias and
this remains possible.
We selected only three specific cognitive subdomains as secondary
outcomes. It is possible that effects on other specific cognitive
subdomains could have been missed.
Where cognition is measured using several different instruments,
it can be difficult to categorise instruments into specific cognitive
subdomains and tomake data pooling decisions. We tried to avoid
bias by using a prespecified, hierarchical list of themost commonly
used instruments, but it is possible that different categorisations
could have led to different results.
Agreements and disagreements with other
studies or reviews
We are not aware of other reviews of similar scope. The Collab-
oration of B-vitamin Treatment Trialists have conducted a meta-
analysis of data on more than 22,000 older participants who were
not selected for specific cognitive diagnoses (Clarke 2014). This
review found no effect of B vitamins on overall or domain-specific
cognitive function despite lowering serum homocysteine levels by
> 25%. Although not directly relevant to a population with mild
cognitive impairment, this result does not support the hypotheses
that B vitamin supplementation or homocysteine-lowering are ef-
fective means to prevent cognitive decline.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Currently, there is no evidence that any vitamin or mineral supple-
ment is useful for preventing progression from MCI to dementia
or for treating the symptoms of MCI.
Implications for research
Research on vitamin andmineral supplements for the treatment of
mild cognitive impairment should be driven by strong hypotheses
based on preclinical research. Studies should investigate mecha-
nisms by measuring putative mediating factors. Ultimately, longer
and larger studies will be needed to investigate outcomes which are
important to patients, including improved functioning and qual-
ity of life, but at the current stage of research, shorter term stud-
ies with surrogate outcomes (biomarkers or cognitive test scores)
remain suitable for hypothesis testing. Outcomes should be mea-
sured across several cognitive domains using instruments which
are known to be sensitive to small changes in the presence of mild
impairments. Trials should include evaluation of baseline nutri-
tional status and assess how this interacts with treatment. Other
possible moderating factors, based on the hypotheses being tested,
should also be measured.
Although there was no evidence of overall benefit from the studies
included in this review, one study of B vitamins reported a slowing
of brain atrophy in the whole study population and an attempt
to replicate this result is needed. The same study reported that
there may be a beneficial effect of B vitamins on episodic mem-
ory in the subgroup with higher homocysteine levels at baseline.
However, the result of a very large individual patient meta-analysis
which found no effect of homocysteine-lowering with B vitamins
on cognitive ageing in 22,000 older participants without specific
cognitive diagnoses at baseline makes this result less promising to
pursue.
A C K N OW L E D G E M E N T S
The protocol was largely based on a general template constructed
for the development of a larger series of protocols and reviews cov-
ered by a National Institute for Health Research (NIHR System-
atic Reviews Programme Grant). The common protocol covered
four types of intervention, for which some evidence exists that
these may modify the risk of developing cognitive impairments
or dementia. These include vitamin and mineral supplements, ex-
ercise, cognition, and dietary interventions. The general protocol
was inspired by a generic protocol approved by theCochraneMus-
culoskeletal Group for another series of reviews (Da Costa 2012;
Da Costa 2014; Reichenbach 2010; Rutjes 2009a; Rutjes 2009b;
Rutjes 2010).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Jager 2012
Methods 2-arm, placebo-controlled, parallel group, randomised clinical trial, intervention for 2
years (trial short name = VITACOG)
Participants Location: Oxford, United Kingdom. Single centre
Setting of recruitment and treatment: University of Oxford
Sample size:
• Number randomised: 138 in intervention, 133 in comparison
• Number completed: 110 in intervention, 113 in comparison
Participant baseline characteristics:
• Age in years (mean ± SD) : vitamin B: 76.8 ± 5.1, placebo: 76.7 ± 4.8
• Female sex
: vitamin B: 70 (63.6%), placebo: 73 (64.6%)
Inclusion criteria:
• Age >= 70 years
• Study partner available as informant
• MCI. No distinction between amnestic and non-amnestic MCI. Screened with
TICSm (≥ 17 and ≤ 29) and a category fluency test. Also MMSE ≥ 24/30, a
subjective memory complaint with corroboration from a study partner using questions
from the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX)
and normal activities of daily living using five questions from the Cambridge
Behavioural Inventory.
Exclusion criteria:
• A diagnosis of dementia or being treated with anti-dementia drugs
• Active cancer
• Major stroke within past 3 months
• Treatment with methotrexate
• Anti-cancer or anti-epileptic drugs
• Taking folic acid > 300 mg/d, B6 >3 mg/d or vitamin B12 > 1.5 mg/d by mouth
or any dose by injection
Interventions Intervention:
TheB-vitamin group receivedTrioBe PlusWcontaining0.8mg folic acid, 0.5mgvitamin
B12 and 20 mg vitamin B6 once daily
Comparator:
Vitamin-free tablets of similar appearance.
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: MMSE, (also measured: TICSm)
Specific cognitive functioning subdomain: episodic memory: HVLT-R (Hopkins Verbal
Learning Test - Revised with delayed recall)
Specific cognitive functioning subdomain: executive functioning: CLOX, (also mea-
sured: category fluency)
Clinical global impression: global CDR
Functional performance: IQCODE
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de Jager 2012 (Continued)
Total adverse events
Mortality
Biomarker: rate of brain atrophy on volumetric MRI
Source of Funding Charles Wolfson Charitable Trust, Medical Research Council, Alzheimer’s Research
Trust, Henry Smith Charity, Thames Valley Dementias and Neurodegenerative Diseases
Research Network of the UKNational Institute for Health Research, John Coates Char-
itable Trust, and the Sidney and Elizabeth Corob Charitable Trust
Recip AB donated vitamins, Axis-Shield provided assay equipment for homocysteine
Declaration of Interest “AD Smith is named as an inventor on three patents held by the University of Oxford
on the use of folic acid to treat AD or MCI (US6008221; US6127370; PCT/GB2010/
051557); under the University’s rules, he could benefit financially if the patent is ex-
ploited. Drs Refsum and Smith report having in the past received speaking honoraria
from Recip AB, the company that donated the vitamin tablets, and from Axis-Shield,
who make the equipment used to assay homocysteine.”
Notes VITACOG study, ISRCTN 94410159, Eudract Number: 2004-001527-38
ISRCTN trial register entry refers to:
Primary outcome measures:
1. Rate of shrinkage of whole brain and/or brain regions assessed by volumetric MRI
2. Changes in performance on a variety of cognitive tests
Secondary outcome measures:
1. Trial recruitment procedures
2. Conversion to dementia
Protocol refers to:
Primary efficacy endpoints:
Clinical: rate of shrinkage of brain assessed by volumetric MRI, change in memory test
score
Secondary efficacy endpoints:
Diagnosis of dementia by DSM-IV, IQCODE, change in any of the cognitive test
scores. Cognitive tests further defined asMMSE,HVLT, paired associates learning (PAL)
, CLOX, Trailmaking, category fluency, SDMT, Map search/attention task, TICSm
Safety and other endpoints:
Included adverse events, mortality, dropout rates, compliance
Protocol also stated that EQ-5D (quality of life) and Geriatric Depression Scale will be
administered at baseline and 24 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Centralized telephone randomiza-
tion by independent statisticians was used
with full allocation concealment and mini-
mization for age, gender, baseline TICS-M
score and consent for MRI.”
Comment: Appropriately randomised.
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de Jager 2012 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Centralized telephone randomiza-
tion by independent statisticians was used
with full allocation concealment and mini-
mization for age, gender, baseline TICS-M
score and consent for MRI.”
Comment: Appropriate allocation conceal-
ment.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants, study partners, and
those assessing outcomes were blind to the
assignment of intervention”. “The placebo
group received vitamin-free tablets of sim-
ilar appearance”
Comment: Measures taken to blind partic-
ipants and personnel.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Participants, study partners, and
those assessing outcomes were blind to the
assignment of intervention”
Comment: Blinded outcome assessment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Of the 266 participants starting
the intervention, 223 participants (83.8%)
completed the second visit 2 years later”.
Total withdrawals of 20 participants (15%)
from placebo group and 23 participants
(17.3%) from active treatment group
“Fewer clinical measures at follow-up (n =
191) compared with cognitive measures (n
= 223) due to some study partners being
unavailable to complete the CDR and IQ-
CODE”
Comment: Loss to follow-up < 20% over
24 months and well balanced between
groups
Selective reporting (reporting bias) High risk Cognitive results reported were a subgroup
of those specified in the protocol, consid-
ered by the authors to be “representative of
particular cognitive domains important in
MCI.”
Diagnosis of dementia by DSM-IV and
EQ-5D (quality of life) not reported
Cognitive results were reported by sub-
groups of participants with high or low
tHcy rather than as an overall effect; not
specified in analysis plan in published pro-
tocol (journals.plos.org/plosone/article?
id=10.1371/journal/pone.0012244#s5)
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de Jager 2012 (Continued)
Other bias Low risk No other risks identified.
Eussen 2006
Methods 3-arm, parallel group, randomised, placebo-controlled trial, 24 week’s duration
Participants Location: The Netherlands.
Setting of recruitment and treatment:Free-living older persons and older persons living
in care-facility homes, recruited via mailed health questionnaires
Sample size
• Number randomised: 195, of whom 119 had CDR 0 at baseline and were
included in this review: 38 in vitamin B12 group, 38 in vitamin B12 + folic acid group,
43 in placebo group.
“Randomization was stratified according to MMA concentration at the screening visit
(< and > 0.45 µmol/L), age (< and > 80), sex and MMSE score (< and > 24 points).”
Participant baseline characteristics:
• Age in years (mean ± SD) : vit B12 80.42 ± 5.52, vit B12 + FA 80.82 ± 4.18,
placebo 79.86 ± 4.74.
• Female sex
: vit B12 29/38 (76%), vit B12 + FA 29/38 (76%), placebo 34/43 (79%).
• Cognitive function - MMSE score (mean ± SD): vit B12 28.18 ± 1.43, vit B12 +
FA 28.34 ± 1.40, placebo 27.93 ± 1.80.
Inclusion criteria:
• Aged ≥ 70 years.
• Mild vitamin B12 deficiency defined as (1) a serum vitamin B12 concentration
between 100 and 200 pmol/L, or (2) a serum vitamin B12 concentration between 200
and 300 pmol/L.
• Plasma MMA concentration ≥ 0.32 µmol/L.
• Serum creatinine concentration ≤ 120 µmol/L.
• Ingested 90% or more of capsules during a 2-week placebo run-in period prior to
randomisation.
Exclusion criteria:
• History of cobalamin deficiency.
• Use of cobalamin (> 50 µg/day) or folic acid (> 200 µg/day).
• Surgery or diseases of the stomach or small intestine, anaemia, dementia, life-
threatening diseases, or severe hearing or visual problems
Interventions Intervention:
1) Vitamin B12: 1000 µg vitamin B12 (cyanocobalamin) per day orally for 24 weeks
2) Vitamin B12 and folic acid: 1000 µg vitamin B12 (cyanocobalamin) plus 400 µg folic
acid per day orally for 24 weeks
Comparator:
Placebo capsule.
The placebo capsules contained AVICEL PH102 (Medipulp GmbH, Aschaffenburg,
Germany) as a filler
Use of additional interventions (common to both treatment arm): not reported.
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Eussen 2006 (Continued)
Outcomes Cognitive function
Cognitive function was assessed before and after 24 wk of treatment with the use of
an extensive neuropsychologic test battery that included the domains of attention, con-
struction, sensorimotor speed, memory, and executive function
Cognitive function was assessed by 6 trained and registered neuropsychologists during
the run-in period (baseline) and at week 24 of the intervention during a 1.5 to 2 hour
session
Neuropsychological test battery included:
• finger tapping, computerised;
• motor planning 2 and 3, computerised;
• Figure of Rey copy, immediate recall and delayed recall;
• 15 word learning immediate recall, delayed recall and recognition;
• Trail-making test, part A and part B;
• Digit span forward and backward;
• Raven Progressive Matrices;
• Stroop test;
• Similarities, WAIS;
• Word fluency, letter;
• Word fluency, animals.
Depression measured with Geriatric Depression Scale
Biochemical measures: vitamin B12, methylmalonic acid, holotranscobalamin, homo-
cysteine, red blood cell folate
Source of Funding Study supported by grants fromZON-MW,TheHague,Netherlands; Kellogg’s Benelux,
Zaventem, Belgium; Foundation to Promote Research into Functional Vitamin B12
Deficiency and the European Union BIOMEDDemonstration Project; Nutricia Health
Foundation, Wageningen, Netherlands
Declaration of Interest
Notes Compliance was checked by counting the number of unused capsules remaining in cap-
sule dispensers and by verifying pill counts in the participants’ diaries. Mean compliance
was 99%
Professor Simone Eussen and Professor Lisette de Groot kindly provided data separately
on participants with CDR 0.5 at baseline for inclusion in this review
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized”, no further information.
Allocation concealment (selection bias) Unclear risk No information.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotes: “The capsules given to the sepa-
rate treatment groups were identical in ap-
pearance, smell and taste.” “The study had
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Eussen 2006 (Continued)
a double-blind design.”
Comment: participants and personnel
blind to allocation.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The study had a double-blind de-
sign.” No specific mention of outcome as-
sessors
Comment: outcome assessors probably
blind to allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete outcome data varied between
cognitive tests. For included outcomes,
data available for minimum of 82% of par-
ticipants
In study as a whole, “16% ... were unable to
complete the trial,mostly because of illness,
and the dropout rate was slightly higher in
the vitamin B12 + folic acid group than in
the other groups.”Dropout inwhole study:
10/64 B12, 15/66 B12 + folic acid, 8/65
placebo
Comment: major effect of differential
dropout unlikely.
Selective reporting (reporting bias) Low risk All outcomes mentioned in methods fully
reported.
Other bias Low risk No other biases identified.
Fan 2017
Methods 2-arm, parallel group, randomised, controlled trial, 6 months duration
Participants Location: China, Shandong (Weifang), single centre.
Setting of recruitment and treatment: community.
Sample size
• Number randomised: 40 in intervention, 40 in comparator.
• Number completed: 38 in intervention, 37 in comparator.
Participant baseline characteristics:
• Age in years (mean ± SD) : intervention 65.45 ± 2.89, comparator 66.37 ± 1.93.
• Female sex
: intervention 20/40 (50%), comparator 22/40 (55%).
• Cognitive function - MMSE score (mean ± SD): intervention 24.88 ± 0.93,
comparator 24.61 ± 0.85.
Inclusion criteria:
• Complaints of memory issues by participant, family members, or others who are
well-informed;
• Mini-Mental State Examination (MMSE) score ≤ 26; Global Deterioration Scale
(GDS) grade 2 to 3, Activities of Daily Living (ADL) score ≤ 18;
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• Cognitive impairment > 3 months;
• Memory test results 1.5 standards deviations below normal controls matched for
age and education;
• Aged 60 to 75 years.
Exclusion criteria:
• Diagnosed with dementia, or any other disease which leads to brain function
disorder;
• Severe disease of heart, liver, lung, kidney etc., severe anaemia, severe
malnutrition, thyroid problem, or folic acid deficiency;
• Severe vision and hearing impairment;
• Taken folic acid supplement within last month.
Interventions Intervention:
400 µg folic acid per day orally for 6 months.
Comparator group:
No intervention, maintenance of their usual lifestyle and eating habits
Use of additional interventions (common to both treatment arm): not reported.
Outcomes Overall cognitive function: MMSE (also measured: MoCA).
Functional performance: Activities of Daily Living (ADL) scale
Source of Funding Not reported.
Declaration of Interest No declarations.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table
“
” (page 4161)
Allocation concealment (selection bias) Unclear risk No information
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
On the first day of each month, subjects in
the experimental group were given a bottle
of folic acid (400µg/tablet, 30 tablets/bot-
tle) by research staff in community. They
were instructed to take one tablet per day
Research staff contacted participants regu-
larly and recorded the usage of folic acid
in the intervention group. No mention of
contact with comparator group
“
µ
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Fan 2017 (Continued)
”
“
” (page 4161)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information
Incomplete outcome data (attrition bias)
All outcomes
Low risk 75/80 (94%) completed trial. 3 dropped
out in control arm, and 2 dropped out in
intervention arm. 2 cases excluded formiss-
ing more than 5 doses, 3 cases voluntary
dropout, group allocations not reported.
Results reported only for the 75 partici-
pants who completed the trial
Selective reporting (reporting bias) Low risk Results were reported for all outcomes
mentioned in the Methods section of pa-
per. No protocol identified
Other bias Low risk No other sources of bias identified.
Krikorian 2010
Methods 2-arm, placebo-controlled, randomised, controlled trial, duration 12 weeks
Participants Location: Cincinnati, Ohio, USA. Single centre.
Setting of recruitment and treatment: Recruitment via advertisement for volunteers
with mild memory problems. Study conducted at Department of Psychiatry and Neu-
roscience, University of Cincinnati College of Medicine
Sample size:
• Number randomised: 15 in intervention, 11 in comparison.
• Number completed: 15 in intervention, 11 in comparison.
Participant (Baseline) characteristics:
• Age in years (mean ± SD): CrPic: 72.2 ± 7.0, placebo 69.8 ± 4.7
Inclusion criteria:
• Elderly individuals with CDR (Clinical Dementia Rating scale) classification of 0.
5, indicating early memory decline consistent with MCI.
Exclusion criteria:
• Diabetes;
• Liver or kidney disease;
• Substance abuse disorder;
• Diagnosed with a psychiatric or neurological condition.
Interventions Active intervention:
Chromium picolinate (CrPic) containing 1000 mcg elemental chromium once daily for
12 weeks
Comparator:
Placebo once daily.
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Krikorian 2010 (Continued)
Outcomes Outcomes of interest in the review:
Specific cognitive functioning subdomain: episodic memory: California Verbal Learning
Test (CVLT)
Source of Funding Funding and material support for this research was provided by Nutrition 21, Inc.,
Purchase, NY, USA
Declaration of Interest No declarations provided.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Enrolled subjects were randomly
assigned in a double-blind manner to re-
ceive chromium picolinate (CrPic), con-
taining 1000 mcg elemental chromium, or
placebo for 12 weeks”
Comment: Insufficient information about
sequence generation.
Allocation concealment (selection bias) Unclear risk Comment: Method of allocation conceal-
ment not described in the paper
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “double-blind”.
Comment: Insufficient information re-
garding the blinding of participants and
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “double-blind”
Comment: Insufficient information in the
paper for judgement on the level of risk
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: The paper did not mention any
participants lost to follow-up or missing
data
Selective reporting (reporting bias) Low risk No protocol available. All outcomes men-
tioned in Methods section reported
Other bias Low risk No other risks identified.
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Naeini 2014
Methods 2-arm, parallel group, randomised, controlled trial, 1 year duration
Participants Location: Iran. Single centre.
Setting of recruitment and treatment: Tehran University, School of Nutritional Sci-
ences and Dietetics
Sample size:
• Number randomised: 148 in intervention, 148 in comparator (total 296).
• Number completed: 127 in intervention, 129 in comparator (total 256).
Participant (baseline) characteristics:
• Age in years (mean ± SD): 66.5 ± 0.39 in vitamin supplementation group, 66.3 ±
0.38 in control group.
• Sex: 53% female among study completers.
Inclusion criteria:
• MMSE scores between 21 and 26;
• Minimum education to fifth grade;
• Age between 60 and 75 years.
Exclusion criteria:
• Dementia, depression, or epilepsy;
• Mental retardation, history of brain surgery, or any significant neurological
disease;
• Severe cardiovascular disease and severe anaemia;
• Severe kidney or liver disease, inflammatory intestinal disease, and any disease
that interfered with the antioxidant’s absorption;
• Consumption of antioxidant medication or vitamin that might modify the results;
• BMI more than 30;
• Special diet (vegetarian, vegan, etc.);
• Smoking;
• Addicted to alcohol;
• Using neuroleptic drugs, benzodiazepine, immunosuppressant, anti-depression
and anticonvulsants medication;
• Current medication known to influence vitamin E and C status (laxatives and
hormone replacement therapy).
Interventions Active intervention:
300 mg of vitamin E (Dl-alpha- tocopherol acetate) plus 400 mg vitamin C (ascorbic
acid) daily for a year
Comparator:
Placebo.
Outcomes Outcomes of interest in the review:
Overall cognitive function: MMSE.
Source of Funding This study was supported by Institute of Nutritional Sciences, University of Vienna and
the Vice-chancellor for Research, Tehran University of Medical Sciences (TUMS), Iran,
by a Grant (No. 11126)
Declaration of Interest ”The authors declare that there are no conflicts of interest“
Notes
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Naeini 2014 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: ”The MCI subjects were divided
to two groups according to their gender
(male or female), each of them were fur-
ther divided to three age groups including
60-65, 65-70, and 70-75 years. The sub-
jects within each of these six groups were
then further divided to two equally num-
bered supplemented or placebo subgroups
by simple randomization“
Comment: Insufficient information about
sequence generation process
Allocation concealment (selection bias) Unclear risk Comment: No information - allocation
concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as ”double-blind“.
Quote: “One group consumed 300 mg of
vitamin E (Dl-alpha- tocopherol acetate)
plus 400 mg vitamin C (ascorbic acid)
per day, and the second group consumed
placebo with the identical condition over
the 1-year intervention period”
Comment: Unclear from this whether ap-
pearance of supplements and placebo were
identical
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Evaluation of cognitive function
by MMMSE was blindly performed by an
expert psychologist.”
Comment: Blinded outcome assessor.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Of the 761 volunteers, 296 were
found to have MCI and selected for the
next part of the study. From these, 40 did
not continue with the study due to the
problems tolerating the supplementations
(14 subjects), 1 subject died, and 25 sub-
jects abstained to continue participation
due to personal reasons. 148 were ran-
domised to each group and 256 subjects
completed the study.” 21/148 in the vi-
tamins group and 19/148 in the placebo
group did not complete
Comment: The participants who did not
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complete the trial (40/296, 13.5%) were
not included in the analysis. Reason for ex-
clusion was not described based on the al-
located group
Selective reporting (reporting bias) Low risk Comment: Outcomes specified in the
methods section were reported. No access
to trial protocol
Other bias Low risk No other risks identified.
Petersen 2005
Methods 3-arm, parallel group, randomised, controlled trial, duration 3 years
Participants Location: United States and Canada.
Setting of recruitment and treatment: 69 ADCS sites in the United States and Canada,
between March 1999 and January 2004
Sample size:
• · Number randomised: 257 in intervention, 259 in comparison.
• · Number completed: 185 in intervention, 193 in comparison.
Participant baseline characteristics:
• Age in years (mean ± SD): placebo 72.9 ± 7.6, vitamin E 72.8 ± 7.3.
• Female sex: placebo 121 (47%), vitamin E 119 (46%).
• Cognitive function - MMSE score (mean ± SD): placebo 27.35 ± 1.8, vitamin E
27.20 ± 1.9
Inclusion criteria:
• Amnestic mild cognitive impairment of a degenerative nature (insidious onset and
gradual progression);
• Age 55-90 years, inclusive;
• Study informant available;
• MMSE 24-30;
• Adequate vision and hearing for neuropsychological testing;
• Normal vitamin B12 level and thyroid function studies and non-reactive RPR;
• Electrocardiogram normal or no clinically significant abnormalities;
• CDR 0.5 - Memory box score 0.5 or 1 and No box score greater than 1;
• All subjects and study informants signed.
Exclusion criteria:
• Significant cerebral vascular disease - Modified Hachinski > 4;
• Depression - Hamilton Depression Rating Scale > 12;
• Central nervous system infarct, infection, or focal lesions of clinical significance
on CT or MRI scans;
• Medical diseases or psychiatric disorders that could interfere with study
participation;
• Pregnant, lactating, or of child bearing potential;
• Taking vitamin supplements, other supplements, or a multivitamin;
• Restrictions on concomitant medication usage, including those with significant
cholinergic or anticholinergic effects or potential adverse effects on cognition.
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Interventions Active intervention:
2000 IU of vitamin E and multivitamin containing 15 IU of vitamin E daily. Intial
vitamin E dose was 1000 IU daily, increased to 2000 IU (1000 IU twice daily) after 6
weeks
Comparator group:
Placebo vitamin E and multivitamin containing 15 IU of vitamin E daily
Note: There was a third arm in which participants received donepezil. Both groups of
interest in this review received placebo donepezil
Outcomes Outcomes of interest in the review:
Progression to possible or probable Alzheimer’s disease, defined according to the clinical
criteria of theNational Institute ofNeurological andCommunicativeDiseases andStroke
and the Alzheimer’s Disease and Related Disorders Association
Overall cognitive function: MMSE (also measured: ADAS-cog).
Specific cognitive subdomain: episodic memory: standardised composite z-score incor-
porating ADAS immediate and delayed word-recall scores and the New York University
immediate and delayed paragraph-recall scores
Specific cognitive subdomain: executive function: standardised composite z-score incor-
porating the digits-backward test, Symbol Digit Modalities Test, and number-cancella-
tion test
Clinical global impression: CDR sum of boxes, Global Deterioration Scale
Functional performance: ADCS Mild Cognitive Impairment Activities of Daily Living
Scale
Adverse events: rates of adverse events that occurred in at least 5% of subjects in the
donepezil or vitamin E group and at least two times in the placebo group during the
double-blind phase
Source of Funding Supported by a grant from the National Institute on Aging (UO1 AG10483) (50% of
funding), and by Pfizer and Eisai (50% of funding). DSMNutritional Products donated
the vitamin E
Declaration of Interest Most authors were either employees of a pharmaceutical company funding the study, or
had received fees for various engagements from pharmaceutical companies
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”We used an adaptive allocation
scheme for the treatment assignment, with
theMMSE score, age, and APOE ǫ4 status
as balancing covariates
Comment: Adequate sequence generation
in the study.
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Allocation concealment (selection bias) Low risk Comment: Insufficient information given.
Should be adequate in a large multicentre
well designed study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “In this multicenter, randomized,
double-blind, placebo-controlled, parallel-
group study, whichwas conducted between
March 1999 and January 2004”
Comment: Insufficient information on the
process of double-blinding. Should be ade-
quate in a large multicentre RCT. Placebos
used and identical treatment regimens in
all groups
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A data and safety monitoring
board reviewed the blinded safety data ev-
ery three months during the trial.”.. “veri-
fication by a central review committee that
a participant met these clinical criteria for
Alzheimer’s disease...”
Comment: Should be adequate in a large
trial with safety and central review commit-
tees for main outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 185/257 (72%) in intervention and
193/259 (75%) completed review
Comment: More than 25% dropout from
each arm.
Selective reporting (reporting bias) High risk No protocol identified. Cognitive results
reported as composite z-scores, individual
test results not reported. Number of partic-
ipants in each analysis not reported
Other bias Low risk No other potential biases detected.
Ting 2017
Methods Substudy of the VITATOPS trial, a randomised, 2-arm, parallel group, placebo-con-
trolled trial
Participants Location: VITATOPS was an international, multicentre (20 countries from 4 conti-
nents). This substudy took place in a single study centre of the VITATOPS trial in Sin-
gapore
Sample size
Number randomised: 8164 participants with recent stroke or TIA randomised in VI-
TATOPS. This substudy was of the 230 subjects with recent lacunar stroke and cognitive
impairment no dementia (CIND). 118/230 allocated to B vitamins, 112/230 allocated
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to placebo
Participant baseline characteristics:
• Age in years (mean (range)): 67 (61-73)
• Female sex: 39.6%
• Cognitive function - MMSE score (median (IQR)): B vitamins 24 (22-27),
placebo 25 (21-27).
Inclusion criteria: “patients presenting within 7months of stroke (ischaemic or haemor-
rhagic) or TIA (eye or brain), as defined by standard criteria, are eligible” for VITATOPS.
For this substudy, which took place in a single VITATOPS centre, “patients with recent
lacunar stroke and cognitive impairment no dementia (CIND) who were followed up
every 6 months for 1 to 5 years as per VITATOPS trial protocol were included. CIND
was defined as impairment in at least one domain of the neuropsychological test battery
using education adjusted cut-off values of 1.5 SDs below the established normal means
on individual tests.” Patients who consented for extended cognition study
Exclusion criteria:
• Taking folic acid or vitamin B6 on medical advice;
• Taking methotrexate for any reason;
• Pregnant or at risk of pregnancy;
• Limited life expectancy.
Interventions Intervention:
Folic acid 2 mg, vitamin B6 25 mg, vitamin B12 500 µg once daily
Comparator:
Placebo.
Outcomes “Neuropsychological tests results focusing on attention and executive functions derived
from a standardized cognitive assessment battery that validated for Singaporean elderly
was analysed.”
Standardized MMSE;
Digit span forward;
Digit span backward;
Visual memory span forward;
Visual memory span backward;
Category naming - animals;
Digit cancellation;
Frontal assessment battery.
Other: serum homocysteine.
Source of Funding Singapore Biomedical Research Council and Singapore National Medical Research
Council
Declaration of Interest 6/8 authors: no disclosures. “DrChen has received support from the Biomedical Research
Council, Singapore for current study of vitamin therapy in the prevention of dementia
and cognitive deterioration following stroke from 2004 to 2008.” “Dr EK Tan has
received support from the National Medical Research Council, Duke NUS Graduate
Medical school, and has received honoraria for duties as an editor of European Journal of
Neurology (Wiley publisher) and Parkinsonism Related Disorders (Elsevier Publisher),
and sponsorship from Novartis Pharmaceuticals, GSK Pharmaceuticals and Lundbeck
Pharmaceuticals.”
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Notes 5 of 235 potentially eligible subjects did not consent to participate in this extended
cognition substudy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Parent study (VITATOPS), quote: “a cen-
tral 24-hour telephone service or an inter-
active website ... uses random permuted
blocks stratified by hospital to allocate a
treatment pack number.”
Allocation concealment (selection bias) Low risk Parent study (VITATOPS), quote: “a cen-
tral 24-hour telephone service or an inter-
active website ... uses random permuted
blocks stratified by hospital to allocate a
treatment pack number.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind”. Parent study (VI-
TATOPS), quote “the tablets being either
vitamin supplements or matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No specific information about site investi-
gators. Likely blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk “The number of the study participants at
the end of each study year from year one
till year five for active and placebo group
was 97, 83, 73, 45, 33 and 93, 75, 59, 38,
27 respectively.”
Selective reporting (reporting bias) Unclear risk Quote: “Neuropsychological tests (sic) re-
sults focusing on attention and executive
functions derived from a standardized cog-
nitive assessment battery that validated (sic)
for Singaporean elderly was analysed.” No
protocol for substudy identified. Not clear
if any outcomes were measured in addition
to those reported
Other bias Low risk No other sources of bias identified.
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van Uffelen 2008
Methods The FACT study (Folate physical Activity Cognition Trial).
2 x 2 factorial, randomised controlled trial (RCT) comparing the effects of (1) a walking
programme with a placebo activity programme, and (2) vitamin B supplementation with
placebo supplementation over 1 year
Participants Location: Netherlands.
Setting of recruitment and treatment: Community setting in a Dutch town.
Sample size:
• Number randomised: 90 in intervention, 89 in comparison.
• Number completed: 71 in intervention, 67 in comparison.
Participant baseline characteristics:
• Age (mean (SD)): Men vitamin B (n = 44) = 75 (2.7); Men placebo (n = 41) = 74
(2.9); women vitamin B (n = 34) = 76 (2.9); women placebo (n = 33) = 76 (2.9).
• MMSE (median (25th-75th percentile): Men vitamin B (n = 44) = 28 (28-29);
men placebo (n = 41) = 29 (28-29); women vitamin B (n = 34) = 29 (29-30); women
placebo (n = 33) = 29 (28-30).
Inclusion criteria:
• Memory complaints (answer “yes” to question “do you have memory complaints”,
or at least twice answering “sometimes” on the Strawbridge cognition scale 26);
• Objective memory impairment (10 WLT delayed recall ≤5 and percentage
savings ≤100));
• Normal general cognitive function (TICS ≥ 19 and MMSE ≥ 24);
• Intact daily functioning (no report of disability in activities of daily living on
GARS scale 30 except on the item “taking care of feet and toe nails”);
• Absence of dementia;
• Being able to perform moderate intensity physical activity without making use of
walking devices - for example, a rollator or a walking frame.
Exclusion criteria:
• Using vitamin supplements/vitamin injections/drinks with folic acid, vitamins B-
12 and B-6, comparable to the vitamin supplement given in the intervention;
• Suffering from epilepsy, multiple sclerosis, Parkinson’s disease, kidney disorder
requiring haemodialysis, psychiatric impairment;
• Suffering from depression as measured by the Geriatric Depression Scale (cut off
(5));
• Using medication for rheumatoid arthritis or psoriasis which interfered with the
vitamin supplement;
• Alcohol abuse (men 21 drinks a week, women 15 drinks a week);
• Currently living in a nursing home or on a waiting list for a nursing home.
Interventions Active intervention:
5 mg folic acid, 0.4 mg vitamin B-12 (cyanocobalamin) and 50 mg vitamin B-6 (pyri-
doxine hydrochloride) once daily for a year
Comparator:
Placebo.
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: MMSE;
Specific cognitive functioning subdomain: episodic memory: Auditory Verbal Learning
Test (AVLT);
Specific cognitive functioning subdomain: executive functioning: Stroop Colour Word
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Test-Abridged (SCWT-A), (also measured: letter fluency);
Specific cognitive functioning subdomain: speed of processing: Digit Symbol Substitu-
tion Test (DSST);
Quality of life: Dementia - quality-of-life (D-QOL), (also measured: health-relatedQoL
with SF-12);
Adverse events.
Source of Funding Funded by Body@Work, Research Center Physical Activity, Work and Health, TNO-
VU University Medical Center. External financial support was obtained from the mu-
nicipality of Alkmaar and the “Stichting Fonds voor het Hart”
VIATRIS provided the FA/B12/B6 pills and placebo pills.
Declaration of Interest ”None of the external sources had input into protocol development, data collection,
analyses, and interpretation or drafting this manuscript
Notes International Standard Randomised Controlled Trial Number Register (ISCTRN)
19227688
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: After the baseline interview, partic-
ipants were randomised using the option
“random sample of cases” in SPSS
Comment: Computer software used for
randomisation leading to adequate se-
quence generation in the study
Allocation concealment (selection bias) Unclear risk Quote: “Participants and exercise instruc-
tors were blinded to group allocation by
being left unaware of which exercise pro-
gramme was supposed to be effective. The
pills were coded as A or B by the manufac-
turer. The key was decoded after data anal-
ysis”
Comment: Further information required.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Pills were coded A or B by man-
ufacturer and then decoded only after data
analysis”
Comment: Participants andpersonnel were
blinded to the intervention a participant
received
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “All cognitive outcome measures
were assessed by trained examiners, who
were also blinded to group allocation”
Comment: Low risk of detection bias as the
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examiners were blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “For both interventions, data were
analysed on a modified intention-to-treat
basis, including participants with at least
one post-baseline assessment”
Comment: All participants accounted for
and data analysed from all participants with
an intention-to-treat method
Selective reporting (reporting bias) Low risk Quote: “The walking program and/or FA/
B12/B6 supplementation were not effec-
tive in improving cognition within one
year”
Comment: The only outcome measure
tested was cognitive function and this was
included in the results
Other bias Low risk No other potential biases detected.
AD:Alzheimer ′sdisease
ADAS-cog: Alzheimer’s Disease Assessment Scale - cognitive
ADCS: Alzheimer’s Disease Cooperative Study
ADL: Activities of Daily Living
APOE ǫ4: Apolipoprotein-E gene, ǫ4 allele
AVLT: Auditory Verbal Learning Test
CAMDEX: Cambridge Mental Disorders of the Elderly Examination
CDR: Clinical Dementia Rating scale
CIND: Cognitive Impairment - no dementia
CLOX: Clock drawing executive test
CrPic: Chromium picolinate
CT: Computerised tomography
CVLT: California Verbal Learning Test
D-QOL: Dementia Quality of Life questionnaire
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition
DSST: Digit Symbol Substitution Test
EQ-5D: Euroqol-5D: a standardized instrument for use as a measure of health outcome
FA: Folic acid
GARS: Groningen Activity Restriction Scale
HVLT: Hopkins Verbal Learning Test
holoTC: Holotranscobalamin
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly
IQR: Interquartile range
ISRCTN: International Standard Randomised Controlled Trial Number
MCI: Mild cognitive impairment
MMA: Methylmalonic acid
MMSE: Mini-Mental State Examination
MoCA: Montreal Cognitive Assessment
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MRI: Magnetic resonance imaging
PAL: Paired Associate Learning
QoL: Quality of life
RBC: Red blood cell
SCWT-A: Stroop Color-Word Test - Abridged
SDMT: Symbol Digit Modalities Test
SF-12: 12-item Short Form Survey
TIA: Transient Ischaemic Attack
TICS28: 28-item Telephone Interview for Cognitive Status
TICSm: Modified Telephone Interview for Cognitive Status
vit: vitamin
WAIS: Wechsler Adult Intelligence Scale
wk: week
10 WLT: 10 Word Learning Test
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abbasi 2013 No cognitive outcomes.
Anand 2011 Wrong population. Participants cognitively healthy.
Andreeva 2011 Wrong population. Participants cognitively healthy.
Anonymous 2008 Wrong design. Not an RCT.
Arwert 2003 Ineligible intervention. Duration of intervention three weeks
Benton 1995 Wrong population. Participants cognitively healthy.
Bryan 2002 Ineligible intervention. Duration of intervention five weeks
Chan 2010 Ineligible intervention. Combined amino acids and vitamins.
Chandra 2001 Other reason: retracted report.
Clarke 2003 Wrong population. Approximately 2/3 of participants had a diagnosis of de-
mentia
Cockle 2000 Wrong population. Participants cognitively healthy.
Corless 1987 Wrong population.
Dangour 2011 Wrong population. Participants were cognitively healthy.
Durga 2007 Wrong population. Participants were cognitively healthy.
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Ford 2008 Wrong population. Participants were cognitively healthy.
Ford 2010 Wrong population. Participants were cognitively healthy.
Grodstein 2007 Wrong population. Participants were cognitively healthy.
Grodstein 2013 Wrong population. Participants were cognitively healthy.
Hankey 2013 Wrong population. Participants were cognitively healthy (after stroke)
Harris 2012 Wrong intervention: included probiotics and herbal extracts.
Heart Protection Study Collaborative Group 1999 Wrong population. Participants were cognitively healthy.
Hvas 2004 Wrong intervention. Duration of intervention was four weeks; administered
parenterally
Kang 2006 Wrong population. Participants were cognitively healthy.
Kang 2008 Wrong population. Participants were cognitively healthy.
Kang 2009 Wrong population. Participants were cognitively healthy.
Kesse-Guyot 2011 (SUVIMAX trial) Wrong population. Participants were cognitively healthy.
Kryscio 2017 Wrong population. Participants were cognitively healthy.
Kwok 2011 Wrong population. Participants had dementia.
Kwok 2017 Wrong population: Participants were mixed population with CDR 0 or CDR
0.5 at baseline
Lewerin 2005 Wrong population. Participants were cognitively healthy.
Loriaux 1985 Ineligible intervention. Duration of treatment was eight weeks
Macpherson 2012 Wrong population: elderly women who responded ’yes’ to the single question
“Do you feel like your memory is getting worse?” Wrong intervention: “mul-
tivitamin, antioxidant and mineral formula with added herbal and antioxidant
plant extracts.”
Maniam 2004 Wrong population: probably healthy older people. Only an abstract has been
published since 2004
Maylor 2006 (ZENITH study) Wrong population. Participants were cognitively healthy.
McMahon 2006 Wrong population. Participants were cognitively healthy.
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McNeill 2007 Wrong population. Participants probably mainly cognitively healthy although
no baseline assessment conducted
Murray-Kolb 2011 Wrong population. Participants were cognitively healthy.
NCT00903695 Wrong intervention. Intervention consisted of vitamins and amino acids
NCT01095211 Wrong intervention. Duration of Intervention 45 days.
NCT01317849 Withdrawn (status posted on ClinicalTrials.gov on August 20, 2014)
NCT01708005 Wrong intervention. Intervention contained PUFAs and grape extract as well
as vitamins and minerals
NCT02467153 Wrong outcomes.
Pase 2015 Wrong intervention. Intervention included fatty acids.
Pathansali 2006 Wrong population. Participants were cognitively healthy.
Wrong intervention. Duration of treatment four weeks.
Rietsema 2014 Wrong design. Case report.
Rossom 2012 Wrong population. Participants were cognitively healthy.
Sanchez 2011 Wrong population. Participants were “apparently healthy”, mean MMSE 26.7
± 2.7
Satalich 2014 Wrong design.
Smith 1999 Wrong population: excluded if MMSE < 18, but no information on mean
MMSE; likely to have included healthy participants and participants with de-
mentia
Summers 2010 Wrong intervention. Intervention included components other than vitamins
and minerals
van der Zwaluw 2014 Wrong population. Participants were cognitively healthy.
Walker 2012 Wrong population. Participants were cognitively healthy.
Wolters 2005 Wrong population. Participants were cognitively healthy.
Wouters-Wesseling 2005 Wrong intervention. Intervention included components other than vitamins
and minerals
Yaffe 2004 Wrong population. Participants were cognitively healthy.
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CDR:ClinicalDementiaRatingscale
MMSE: Mini-Mental State Examination
PUFA: Polyunsaturated Fatty Acid
Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12607000321448
Methods Randomised placebo controlled trial.
Participants Location: Australia. Single centre.
Setting of recruitment and treatment: WA Centre for Health & Ageing, University of Western
Australia
Inclusion criteria:
• Adults with mild cognitive impairment (-1.5 standard deviations below norm on any task in
the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological
battery);
• Over 65 years of age;
• Vitamin D concentration between 12.5 and 50 nmol/L at baseline.
Exclusion criteria:
• · Diagnosis of osteoporosis requiring treatment;
• · No informant available;
• · Severe physical or medical illness that would preclude completion of the trial;
• · Hearing or visual impairment that would preclude assessments;
• Already in an intervention trial;
• · Clinical history of stroke;
• · Fall in the last 3 months;
• · Heart attack in the last 3 months;
• · Fall with fracture over the age of 65 years;
• · History of kidney or bladder stones;
• · Current acute depression;
• · History of schizophrenia;
• · Current diagnosis of dementia.
Interventions Intervention :
1000 IU vitamin D daily by oral tablet.
Comparator group:
Placebo (soyabean oil tablet indistinguishable from active tablet)
Outcomes Outcomes of interest in the review:
Overall cognitive functioning: Cambridge Examination for Mental Disorders in the Elderly - Cog-
nitive section (CAMCOG);
Specific cognitive functioning subdomain: executive function: digit-symbol coding task;
Specific cognitive functioning subdomain: episodic memory: California Verbal Learning Scale-Re-
vised;
Development of dementia;
Quality of life: SF-12.
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Reason awaiting classification Only publication of baseline results and protocol found. No results available after contact with
authors
Notes National Health and Medical Research Council Dementia Research Grants Program
Jiang 2014
Methods Randomised controlled trial. No information on randomisation methods
Participants “120 patients with VCIND complicated by HHcy were randomly selected”. All were “patients with
cerebral apoplexy that received treatment at the First Hospital Affiliated to the Chinese PLA General
Hospital”
Interventions Experimental intervention: “5 mg of extra folic acid per day and 500 mcg of mecobalamin thrice per
day for 24 weeks, apart from conventional treatment.”
Control group: presumed conventional treatment only (not specified)
Outcomes Montreal Cognitive Assessment (MoCA)
Reason awaiting classification Multiple pieces of information sought from authors about methods and results. Unusual age profile
of participants. First email sent 19/05/17. No response received by 23/05/18
Notes
Ma 2017
Methods Randomised controlled trial. No information on randomisation methods other than “random cluster
sampling.”
Participants 180 community-dwelling people with MCI (modified Petersen’s criteria) in the Binhai NewDistrict,
Tainjin, China
Interventions Experimental intervention: Folic acid 400 mcg daily. Control intervention: conventional treatment
Outcomes Chinese version of Wechsler Adult Intelligence Scale - Revised (WAIS-RC)
Reason awaiting classification Multiple pieces of information sought from authors about methods, sample size, and results. No
response received by 23/05/18
Notes Outcomes at different time points (6, 12, and 24 months) are reported in three separate papers
CAMCOG:CambridgeCognitionExamination
HHcy: high homocysteine
MCI: Mild cognitive impairment
MoCA: Montreal cognitive assessment
SF-12: 12-item Short Form Survey
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VCIND: Vascular cognitive impairment (no dementia)
WAIS-RC: Wechsler Adult Intelligence Scale - Revised (China)
Characteristics of ongoing studies [ordered by study ID]
NCT02185222
Trial name or title Effect of vitamin D on cognitive decline of patients with memory complaint (trial short name = D-COG)
Methods RCT, triple-blind.
Participants Aged 60+; both genders; “report to a memory centre with symptoms of memory complaint”; MMSE score
“> the 5th percentile for sociocultural level of the patient”, no dementia
Interventions Experimental: Cholecalciferol 100 000 IU per month as a single dose, administered as oral solution. Control:
placebo. Duration: 2 years
Outcomes Primary outcome: change from baseline on total recall test from Free and Cued Selective Reminding Test
Secondary outcomes: multiple general and domain-specific cognitive tests; all adverse events; several bio-
chemical outcomes
Starting date July 2014
Contact information Sponsored by University Hospital, Tours. Contact fanny.hennekinne@univ-tours.fr
Notes Estimated completion date July 2018.
MMSE:Mini−mentalstateexamination
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D A T A A N D A N A L Y S E S
Comparison 1. B vitamins versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive function
(MMSE)
3 488 Mean Difference (IV, Random, 95% CI) 0.44 [-0.23, 1.12]
2 Episodic memory 3 397 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.10, 0.29]
3 Executive function 3 392 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.23, 0.29]
4 Speed of processing 2 173 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.26, 0.34]
5 Quality of life (D-QOL) 1 138 Mean Difference (IV, Random, 95% CI) 0.0 [-0.10, 0.10]
6 Functional performance (ADL) 1 75 Mean Difference (IV, Random, 95% CI) -0.78 [-1.35, -0.21]
Comparison 3. Vitamins E and C versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cognitive function
(MMSE)
1 256 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.25, 0.71]
Analysis 1.1. Comparison 1 B vitamins versus placebo, Outcome 1 Overall cognitive function (MMSE).
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 1 Overall cognitive function (MMSE)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jager 2012 110 27.85 (2.24) 113 27.65 (2.26) 30.1 % 0.20 [ -0.39, 0.79 ]
Fan 2017 38 26.03 (1.01) 37 24.89 (1.21) 32.0 % 1.14 [ 0.63, 1.65 ]
Ting 2017 97 0.028 (0.47) 93 -0.02 (0.79) 37.9 % 0.05 [ -0.13, 0.24 ]
Total (95% CI) 245 243 100.0 % 0.44 [ -0.23, 1.12 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 15.73, df = 2 (P = 0.00038); I2 =87%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours B vitamins
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Analysis 1.2. Comparison 1 B vitamins versus placebo, Outcome 2 Episodic memory.
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 2 Episodic memory
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jager 2012 110 7.4 (3.5) 113 6.9 (3.54) 57.2 % 0.14 [ -0.12, 0.40 ]
Eussen 2006 26 3.5 (2.8) 10 2.6 (2.99) 7.4 % 0.31 [ -0.42, 1.04 ]
van Uffelen 2008 71 5.22 (2.94) 67 5.29 (2.62) 35.5 % -0.02 [ -0.36, 0.31 ]
Total (95% CI) 207 190 100.0 % 0.09 [ -0.10, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 B vitamins versus placebo, Outcome 3 Executive function.
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 3 Executive function
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
de Jager 2012 110 13.05 (1.85) 113 12.65 (2.1) 50.8 % 0.20 [ -0.06, 0.46 ]
Eussen 2006 21 -2.65 (1.15) 10 -2.32 (0.63) 10.6 % -0.32 [ -1.07, 0.44 ]
van Uffelen 2008 71 -60.88 (23.83) 67 -58.83 (18.97) 38.6 % -0.09 [ -0.43, 0.24 ]
Total (95% CI) 202 190 100.0 % 0.03 [ -0.23, 0.29 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours B vitamins
Analysis 1.4. Comparison 1 B vitamins versus placebo, Outcome 4 Speed of processing.
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 4 Speed of processing
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Eussen 2006 24 90 (55.98) 11 84.91 (39.54) 17.9 % 0.10 [ -0.62, 0.81 ]
van Uffelen 2008 71 36.4 (11.48) 67 36.1 (8.77) 82.1 % 0.03 [ -0.30, 0.36 ]
Total (95% CI) 95 78 100.0 % 0.04 [ -0.26, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours placebo Favours B vitamins
69Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 B vitamins versus placebo, Outcome 5 Quality of life (D-QOL).
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 5 Quality of life (D-QOL)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
van Uffelen 2008 71 3.5 (0.33) 67 3.5 (0.27) 100.0 % 0.0 [ -0.10, 0.10 ]
Total (95% CI) 71 67 100.0 % 0.0 [ -0.10, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 B vitamins versus placebo, Outcome 6 Functional performance (ADL).
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 1 B vitamins versus placebo
Outcome: 6 Functional performance (ADL)
Study or subgroup Experimental Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fan 2017 38 15.92 (1.2) 37 16.7 (1.33) 100.0 % -0.78 [ -1.35, -0.21 ]
Total (95% CI) 38 37 100.0 % -0.78 [ -1.35, -0.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0077)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours B vitamins Favours placebo
Analysis 3.1. Comparison 3 Vitamins E and C versus placebo, Outcome 1 Overall cognitive function
(MMSE).
Review: Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
Comparison: 3 Vitamins E and C versus placebo
Outcome: 1 Overall cognitive function (MMSE)
Study or subgroup Vitamins E + C Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Naeini 2014 127 26.82 (1.91) 129 26.59 (2.04) 100.0 % 0.23 [ -0.25, 0.71 ]
Total (95% CI) 127 129 100.0 % 0.23 [ -0.25, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours placebo Favours vitamins E + C
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A P P E N D I C E S
Appendix 1. Biological plausibility of Vitamins and Minerals
Supplement* Summary of action Biological plausibility
Vitamins
Vitamin A antioxidant;
anti-inflammatory;
anticholinesterase;
beta-amyloid inhibition
Carboxylic formofVitaminAknownas all-
trans retinoic acid has been shown to have
memory restorative function and it may
be attributed to its anticholinesterase, an-
tioxidative and antiinflammatory potential
(Sodhi 2013).VitaminA andbeta-carotene
may also inhibit the formation, extension,
and destabilising effects of beta-amyloid
fibrins. Plasma or cerebrospinal fluid con-
centrations of vitamin A and beta-carotene
have been reported to be lower in AD pa-
tients, and increased Vit A/beta-carotene
concentrations have been clinically shown
to slow the progression of dementia (Ono
2012).
Vitamin D neuronal activity Vitamin D receptor (VDR) and 1, al-
pha-hydroxylase, the terminal calcitriol-ac-
tivating enzyme, are distributed through-
out both the foetal and adult brain. This
is thought to play a role in brain de-
velopment and critical brain functions (
McCann 2008). Significant correlation be-
tween serum 25(OH)D levels and cogni-
tive scores were reported in De Luca 1975
and Przybelski 2007.
Vitamin E antioxidant;
beta-amyloid inhibition
Vitamin E consists of a group of toco-
pherols and tocotrienols. Apart from lipid
antioxidant activity, other functions in-
clude membrane stabilisation by forming
complexes with the products of lipid hy-
drolysis (Wang 2000). It has been shown
that the antioxidant and free radical scav-
enging activity of Vitamin E inhibits amy-
loid beta protein-induced neuronal cell
death and may have implication in preven-
tion and treatment of Alzheimer’s demen-
tia. (Behl 1992).
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Vitamin K neuronal activity Vitamin K participates in the synthesis of
sphingolipids. Sphingolipids participate in
important cellular events such as prolifer-
ation, differentiation, senescence, and cell-
cell interactions. Sphingolipid metabolism
has been linked to age-related cognitive de-
cline and neurodegenerative diseases such
as Alzheimer’s disease (Ferland 2012). A
cross-sectional study found correlations be-
tween higher serum phylloquinone con-
centration and better cognitive scores in
tests evaluating episodic verbal memory
among healthy older adults (Ferland 2013)
.
Thiamine
(Vitamin B1)
neuronal activity Thiamine is required as a cofactor in the
cellular production of energy and enhances
normal neuronal activities (Osiezagha
2013). Rats with an episode of induced thi-
amine deficiency had cognitive, learning,
and memory impairments (Langlais 1995)
.
Riboflavin
(Vitamin B2)
neuronal activity Riboflavin (7,8-dimethyl-10-ribityl-isoal-
loxazine) is water-soluble. Symptoms of
neurodegeneration and peripheral neu-
ropathy in riboflavin deficiency have been
documented in animal studies, but not ob-
served in humans. Subclinical riboflavin
deficiencymay contribute to increased con-
centrations of plasma homocysteine and
may be associatedwith increased risk of car-
diovascular disease and impaired handling
of iron (Powers 2003).
Niacin
(Vitamin B3)
vascular:
anti-inflammatory
Niacin is a water-soluble precursor cofac-
tor essential for the formation of dozens
of enzymes. Niacin decreases atheroscle-
rosis development mainly by reducing
LDL cholesterol. It also has modest HDL-
cholesterol-raising and anti-inflammatory
effects (Kühnast 2013).
Niacin deficiency causes pellagra. Its neu-
ropsychiatric symptoms are similar to those
in Alzheimer’s disease or vascular dementia
(Amanullah 2010).
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Vitamin B6
(Pyridoxine, pyridoxal, pyridoxamine,
Pyridoxal 5’ phosphate (PLP) and pyridox-
amine 5’ phosphate (PMP), Pyridoxine 5’-
phosphate (PNP))
homocysteine;
neuronal activity
Vitamin B6 is a group of water-soluble
compounds (vitamers). Pyridoxal 5’ phos-
phate (PLP) and pyridoxamine 5’ phos-
phate (PMP) are the active coenzyme forms
of vitamin B6 (ODS 2014).
Vitamin B6 has many important brain
functions such as biosynthesis of neu-
rotransmitters (GABA, dopamine, nora-
drenaline, serotonin), receptor binding,
macronutrient metabolism, and gene ex-
pression. In a study looking at low plasma
B6 levels predicting cognitive decline and
depression in at-risk individuals, low PLP
status was seen as a risk factor for cogni-
tive decline and depression in at-risk pop-
ulations (Scott 2013).
Folic Acid
(Vitamin B9)
antioxidant;
homocysteine; neuronal activity
Folate is a cofactor and promotes the
remethylation of homocysteine -- an amino
acid that can induce DNA strand breakage,
oxidative stress, and apoptosis. Folate is re-
quired for normal development of the ner-
vous system, playing important roles reg-
ulating neurogenesis and programmed cell
death. Folate deficiency and its resultant
increase in homocysteine levels has been
linked to several neurodegenerative condi-
tions, including stroke, Alzheimer’s disease,
and Parkinson’s disease (Mattson 2003).
Vitamin B12
(cobalamins: cyanocobalamin, hydroxo-
cobalamin, methylcobalamin, hydroxo-
cobalamin)
homocysteine;
neuronal activity
Vitamin B12 acts as a coenzyme in
metabolism of amino acids and fatty acids
required for the synthesis of nucleic acids,
erythrocytes, and in the maintenance of
myelin (Pawlak 2014). Lower vitamin B12
status has been associated with increased
rates of cognitive decline and dementia
(Clarke 2007; O’Leary 2012).
Pantothenic Acid
(Vitamin B5)
energy metabolism Pantothenic acid (PA) is a component of
coenzyme A, an essential cofactor in fatty
acid oxidation, lipid elongation, and fatty
acid synthesis (Kelly 2011). This may have
an indirect effect in cognition.
Biotin
(Vitamin H)
energy metabolism Biotin is also known as Vitamin H and
is part of the B complex group of vita-
mins. They act as cofactors in carboxy-
lase enzymes, fatty acid, and amino acid
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metabolism. This may have an indirect ef-
fect in cognition
Vitamin C antioxidant Vitamin C has antioxidant functions and is
required for the synthesis of noradrenaline
from dopamine. It has been reported that
Vitamin C levels have been lower than con-
trols in patients with senile dementia of
Alzheimer’s type (Jeandel 1989). In a lon-
gitudinal and cross-sectional study, it was
found that higher vitamin C levels were as-
sociated with better memory performance
(Perrig 1997).
Minerals
Calcium neuronal activity Calcium ions regulate a number of physi-
ological processes including neuronal gene
expression and the neuronal secretion of
neurotransmitters (Dolphin 2012; Linus
Pauling Institute). Supplementation with
calcium togetherwith vitaminDwas found
to have no significant association with inci-
dent cognitive impairment (Rossom 2012)
.
Ozawa 2012 concluded that, in the gen-
eral Japanese population, higher self-re-
ported dietary intakes of potassium, cal-
cium, and magnesium reduced the risk of
all-cause dementia, especially Vascular De-
mentia (VaD). The proposed mechanism
was through the reduction of vascular risk
factors
Chromium energy production; metabolism. Chromium is needed for energy produc-
tion and has been found to promote the ef-
fect of insulin involved in metabolism and
storage of protein, carbohydrates and lipids
within the CNS (IOM2011;Ozawa 2012;
Anderson 1997).
Chromium is involved in metabolism of
nucleic acid, which is needed to build
DNA, the genetic material in cells and it
promotes synthesis of cholesterol and fatty
acids needed for brain function. It may
lower LDL cholesterol and triglyceride lev-
els, raise HDL cholesterol levels and reduce
high blood pressure (Preuss 1997).
Insulin resistance is implicated in the
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pathophysiological changes associated with
Alzheimer’s disease, and pharmaceutical
treatments that overcome insulin resistance
improve memory function in subjects with
mild cognitive impairment (MCI) and
early Alzheimer’s disease. Chromium (Cr)
supplementation improves glucose disposal
in patients with insulin resistance and dia-
betes. A double-blind RCT suggested that
supplementation with chromium picoli-
nate can enhance cognitive inhibitory con-
trol and cerebral function in older adults
at risk for neurodegeneration (Krikorian
2010). A positive correlation between cog-
nitive function and serum chromium levels
was found in a study (Smorgon 2004).
Copper antioxidant Copper is a component of an antioxidant
enzyme called superoxide dismutase that
protects cells from damage by harmful free
radicals. Copper is necessary for a healthy
nerve system and taste sensitivity (IOM
2011).
Copper may promote non-amyloidogenic
processing of amyloid precursor protein
(APP) and thereby lowers the Aβ produc-
tion in cell culture systems, and it increases
lifetime and decreases soluble amyloid pro-
duction in APP transgenic mice (Borchardt
1999). In Alzheimer patients, the decline
of Aβ levels in CSF is diminished in the
treatment group (Kaden 2011).
Iodine neuronal activity Iodine is needed for the synthesis of thy-
roid hormones, which, in turn, are needed
for the myelination of the central nervous
system. Iodine is necessary for the normal
development of the brain. A deficiency of
this mineral during critical periods of de-
velopment in gestation can lead to intel-
lectual disability and neurodevelopmental
problems (Bath 2013a).
Positive associationwas found betweenma-
ternal iodine status and child IQ at age 8
years and reading ability at age 9 years (Bath
2013b).
Iron neuronal activity Iron is needed for development of oligo-
dendrocytes and numerous enzymes that
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synthesise neurotransmitters such as nora-
drenaline, serotonin, and dopamine. It is
important for production of the haemo-
globin in red blood cells (Linus Pauling
Institute; IOM 2011).
Regression analysis showed
that nonanaemic iron-deficient adolescent
girls who received iron performed better on
a test of verbal learning and memory than
girls in the control group (Bruner 1996).
Magnesium energy, metabolism Magnesium is involved in hundreds of en-
zyme reactions, including those for form-
ing bone matrix and protein synthesis. It is
vital for fat and carbohydrate metabolism,
and so plays a role in energy produc-
tion; can improve insulin sensitivity in
diabetics and help regulate blood sugar
level; regulates neuromuscular transmis-
sion and higher self-reported dietary in-
takes of potassium, calcium, and magne-
sium reduce the risk of all-cause demen-
tia, especially VaD, in the general Japanese
population (Ozawa 2012).
Manganese metabolism Manganese is needed to synthesise fatty
acids and cholesterol, and metabolise car-
bohydrates and proteins. It is important for
energy production. It promotes utilisation
of other key nutrients like vitamin B1 (thi-
amine), biotin, choline, ascorbic acid, and
vitamin E (Linus Pauling Institute;).
Man-
ganese is needed for glucose metabolism,
which helps regulate blood glucose. It is
needed to make manganese superoxide dis-
mutase (MnSOD), one of the key antiox-
idants that protects cells from free radi-
cal damage, and so helps maintains healthy
nerves. It works synergistically with the B-
complex vitamins to generate an overall
feeling of well-being (IOM 2011).
Molybdenum metabolism Molybdenum promotes normal cell func-
tion. It functions as a cofactor for three
essential enzymes that play a vital role
in carbohydrate metabolism, utilisation of
iron, sulphite detoxification, and uric acid
formation (Linus Pauling Institute; IOM
77Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
2011).
Phosphorus metabolism, neuronal structure and func-
tion
Phosphorus is needed for metabolism of
carbohydrates and fats to produce energy
and is involved in the production of ATP
required for growth and repair of cells and
tissues; needed to make cell membranes. It
helps the body utilise the B-complex vita-
mins that support proper muscle and nerve
function (Linus Pauling Institute; IOM
2011).
Potassium nerve transmission Potassium is involved in regulating nerve
transmissions and muscle contractions. It
helps the body handle sodium and so re-
duce the risk of high blood pressure (Berr
2012). It has been found to lower the risk of
stroke and ischaemic heart disease. Potas-
sium is needed for synthesis of protein from
amino acids (Linus Pauling Institute; IOM
2011).
Higher self-reported dietary intakes of
potassium, calcium, and magnesium re-
duce the risk of all-cause dementia, espe-
cially VaD, in the general Japanese popula-
tion (Ozawa 2012).
Selenium antioxidant Selenium is an important antioxidant es-
pecially in combination with vitamin E. It
has been found to induce repair of DNA
in damaged cells (Linus Pauling Institute;
IOM 2011).
Selenium is a major structural component
of glutathione peroxidases which are im-
portant antioxidant enzymes in the cen-
tral nervous system and other body tissues
(Mehdi 2013; Rahman 2007).
Low selenium levels were found to be re-
lated to a risk factor for cognitive function
(Berr 2012; Smorgon 2004). Supplemen-
tation with selenium has been associated
with an improved overall health, reducing
oxidative stress and ameliorating risk fac-
tors for dementia (Mehdi 2013).
Sodium neuronal activity Sodium is essential for regulating mus-
cle contractions, and nerve transmissions
essential for normal CNS physiologi-
cal mechanisms and homeostasis (Linus
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Pauling Institute; IOM 2011).
Zinc anti-oxidant
neuronal activity
Zinc is a constituent of the antioxidant en-
zyme superoxide dismutase that helps re-
duce the harm from harmful free radicals.
Zinc regulates cell division and synthesis of
genetic cell DNA. It is essential for repro-
duction, repair, and normal growth within
the CNS (Linus Pauling Institute).
Zinc is found in high levels in the brain
where it performs catalytic, structural, and
regulatory roles in cellular metabolism. In
the brain, zinc is bound to proteins but
free zinc is present in synaptic vesicles and
performs a role in neurotransmission me-
diated by glutamate and gamma-aminobu-
tyric acid (GABA). Short-term deficits of
zinc have been shown to impair certain
measures of mental and neurological func-
tion while long-term deficits of zinc, es-
pecially during gestation, results in mal-
formation or deficits in attention, learn-
ing, memory, and neuropsychological be-
haviour (IOM 2011)
Zinc was found to be capable of reducing
post-ischaemic injury to a variety of tis-
sues and organs through a mechanism that
might involve the antagonism of copper re-
activity. Although the evidence for the an-
tioxidant properties of zinc is compelling,
the mechanisms are still unclear (Powell
2000).
* Only orally-administered supplements taken at any dose for at least 12 weeks will be included. Supplements that combine vitamins
or minerals are eligible as well
Appendix 2. Sources searched and search strategies
Source Search strategy Hits retrieved
ALOIS (www.medicine.ox.ac.uk/alois)
(Date of most recent search: 25 January
2018)
Basic search: VIT
(Studies within ALOIS are coded VIT if
the intervention is a vitamin or mineral)
Dec 2014: 254
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 3
Jan 2018: 1
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MEDLINE In-process and other non-in-
dexed citations and MEDLINE 1950 -
present (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp *Vitamins/
2. exp *Minerals/
3. exp *Dietary Supplements/
4. Calcium Carbonate/
5. vitamin*.ti,ab.
6. cholecalciferol.ti,ab.
7. ergocalciferol.ti,ab.
8. toxiferol.ti,ab.
9. retinol.ti,ab.
10. “retinoic acid”.ti,ab.
11. Vitamin A/
12. Vitamin B 12/
13. Vitamin D/
14. Vitamin E/
15. “beta-carotene”.ti,ab.
16. “alpha-carotene”.ti,ab.
17. “gamma-carotene”.ti,ab.
18. “beta-cryptoanthin”.ti,ab.
19. thiamine.ti,ab.
20. riboflavin.ti,ab.
21. niacin.ti,ab.
22. nicotinamide.ti,ab.
23. pantothenic.ti,ab.
24. pyridoxine.ti,ab.
25. pyridoxal.ti,ab.
26. pyridoxamine.ti,ab.
27. biotin.ti,ab.
28. “folic acid”.ti,ab.
29. Folic Acid/
30. cyanocobalamin.ti,ab.
31. methylcobalamin.ti,ab.
32. “l-ascorbic acid”.ti,ab.
33. “ascorbic acid”.ti,ab.
34. ascorbate.ti,ab.
35. Ascorbic Acid/
36. phylloquinone.ti,ab.
37. phytomeadione.ti,ab.
38. phytonadine.ti,ab.
39. mineral*.ti,ab.
40. multivitamin*.ti,ab.
41. “diet* supplement*”.ti,ab.
42. calcium.ti,ab.
43. Calcium/
44. iron.ti,ab.
45. zinc.ti,ab.
46. sodium.ti,ab.
47. potassium.ti,ab.
Dec 2014: 1320
Jul 2015: 53
Mar 2016: 111
Aug 2016: 103
Mar 2017: 166
Jan 2018: 120
80Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
48. phosphorus.ti,ab.
49. magnesium.ti,ab.
50. chloride.ti,ab.
51. sulphur.ti,ab.
52. mangansese.ti,ab.
53. cobalt.ti,ab.
54. selenium.ti,ab.
55. copper.ti,ab.
56. iodine.ti,ab.
57. fluoride.ti,ab.
58. or/1-57
59. *Aging/
60. Aged/
61. “Aged, 80 and over”/
62. Middle Aged/
63. Age Factors/
64. “mild cognitive impairment”.ti,ab.
65. Mild Cognitive Impairment/
66. MCI.ti,ab.
67. AAMI.ti,ab.
68. ACMI.ti,ab.
69. ARCD.ti,ab.
70. CIND.ti,ab.
71. (nMCI or aMCI or mMCI or MCIa).
ti,ab.
72. “old* adults”.ti,ab.
73. elderly.ti,ab.
74. “old* age*”.ti,ab.
75. “middle age*”.ti,ab.
76. seniors.ti,ab.
77. “senior citizens”.ti,ab.
78. “community dwelling”.ti,ab.
79. pensioners.ti,ab.
80. “aged sample”.ti,ab.
81. “aged population”.ti,ab.
82. or/59-81
83. 58 and 82
84. *Cognition/
85. *Cognition Disorders/
86. Memory/
87. Memory Disorders/
88. (cognit* adj3 (func* or declin* or re-
duc* or impair* or improve* or deficit* or
progress* or perform* or abilit*)).ti,ab.
89. “mental perform*”.ti,ab.
90. memory.ti,ab.
91. “executive function*”.ti,ab.
92. Executive Function/
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93. Attention/
94. (speed adj2 processing).ti,ab.
95. “episodic memory”.ti,ab.
96. Memory, Episodic/
97. or/84-96
98. 83 and 97
99. randomized controlled trial.pt.
100. controlled clinical trial.pt.
101. randomized.ab.
102. placebo.ab.
103. drug therapy.fs.
104. randomly.ab.
105. trial.ab.
106. groups.ab.
107. or/99-106
108. exp Animals/ not humans.sh.
109. 107 not 108
110. 98 and 109 [all results]
111. *Vitamins/
112. *Cognition/
113. “Aged, 80 andover”/ orAged/ orMid-
dle Aged/
114. Mild Cognitive Impairment/
115. “mild cognitive impairment”.ti,ab.
116. 113 or 114 or 115
117. 111 and 112 and 116
118. 99 or 100
119. 117 and 118 [results sent directly to
author team]
120. 110 not 119 [results minus those sent
directly to author team. These results will
be screened by the ’crowd’]
Embase
1974 - 24 January 2018 (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp *vitamin/
2. exp *mineral/
3. exp diet supplementation/
4. calcium/
5. vitamin*.ti,ab.
6. mineral*.ti,ab.
7. cholecalciferol.ti,ab.
8. ergocalciferol.ti,ab.
9. toxiferol.ti,ab.
10. retinol.ti,ab.
11. retinal.ti,ab.
12. “retinoic acid”.ti,ab.
13. vitamin D/
14. vitamin B complex/ or vitamin B
group/
15. vitamin D/
Dec 2014: 1275
Jul 2015: 114
Mar 2016: 184
Aug 2016: 94
Mar 2017: 257
Jan 2018: 250
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16. vitamin K epoxide reductase/ or vita-
min K group/
17. colecalciferol/ or calcitriol/ or calcitriol
derivative/
18. ascorbic acid/
19. vitamin supplementation/
20. “beta-carotene”.ti,ab.
21. beta carotene/
22. “alpha-carotene”.ti,ab.
23. alpha carotene/
24. “gamma-carotene”.ti,ab.
25. gamma carotene/
26. “beta-cryptoanthin”.ti,ab.
27. thiamine.ti,ab.
28. thiamine/
29. riboflavin.ti,ab.
30. riboflavin/
31. niacin.ti,ab.
32. nicotinic acid/
33. nicotinamide.ti,ab.
34. pantothenic.ti,ab.
35. pyridoxamine.ti,ab.
36. pantothenic acid/
37. pyridoxamine/
38. biotin.ti,ab.
39. biotin/
40. “folic acid”.ti,ab.
41. folic acid/
42. cyanocobalamin.ti,ab.
43. cyanocobalamin/
44. methylcobalamin.ti,ab.
45. “l-ascorbic acid”.ti,ab.
46. “ascorbic acid”.ti,ab.
47. phylloquinone.ti,ab.
48. phytonadine.ti,ab.
49. phytomeadione.ti,ab.
50. multivitamin*.ti,ab.
51. “vitamin* supple*”.ti,ab.
52. “diet* supplement*”.ti,ab.
53. calcium.ti,ab.
54. iron.ti,ab.
55. iron/
56. zinc.ti,ab.
57. zinc/
58. sodium.ti,ab.
59. sodium/
60. potassium.ti,ab.
61. citrate potassium/ or potassium/ or
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clavulanate potassium/ or diclofenac potas-
sium/
62. phosphorus.ti,ab.
63. phosphorus/
64. magnesium.ti,ab.
65. magnesium/
66. chloride.ti,ab.
67. chloride/
68. sulphur.ti,ab.
69. mangansese.ti,ab.
70. cobalt.ti,ab.
71. cobalt/
72. selenium.ti,ab.
73. selenium/
74. copper.ti,ab.
75. copper/
76. iodine.ti,ab.
77. fluoride.ti,ab.
78. fluoride/
79. or/1-78
80. aging/
81. aged/
82. middle aged/
83. mild cognitive impairment/
84. “mild cognitive impairment”.ti,ab.
85. MCI.ti,ab.
86. AAMI.ti,ab.
87. ACMI.ti,ab.
88. ARCD.ti,ab.
89. CIND.ti,ab.
90. (nMCI or aMCI or mMCI or MCIa).
ti,ab.
91. “middle age*”.ti,ab.
92. “old* age*”.ti,ab.
93. “old* adults”.ti,ab.
94. “community dwelling”.ti,ab.
95. “senior citizens”.ti,ab.
96. seniors.ti,ab.
97. pensioners.ti,ab.
98. “aged sample”.ti,ab.
99. “aged population”.ti,ab.
100. or/80-99
101. exp cognition/
102. cognition disorders/
103. episodic memory/ or memory/
104. memory disorder/
105. dementia/
106. Alzheimer disease/
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107. dement*.ti,ab.
108. alzheimer*.ti,ab.
109. cognition.ti,ab.
110. cognitive.ti,ab.
111. or/101-110
112. 79 and 100 and 111
113. randomized controlled trial/
114. controlled clinical trial/
115. placebo.ab.
116. (random* adj2 divide*).ti,ab.
117. (random* adj2 allocate*).ti,ab.
118. trial.ab.
119. “double-blind*”.ti,ab.
120. “single blind*”.ti,ab.
121. or/113-120
122. 112 and 121
123. *Cognition/
124. exp *vitamin/ or exp *vitamin supple-
mentation/
125. exp *mineral/ or exp *mineral supple-
mentation/
126. (vitamin* or mineral*).ti.
127. 124 or 125 or 126
128. exp *aging/
129. (elderly or “middle age*” or “old*
adults” or MCI or “mild cognitive impair-
ment”).ti
130. exp *middle aged/
131. 128 or 129 or 130
132. 123 and 127 and 131
133. 113 or 114
134. 132 and 133
135. 122 not 134
PsycINFO
1806 - January week 2, 2018 (Ovid SP)
(Date of most recent search: 25 January
2018)
1. exp Aging/
2. exp Cognitive Impairment/
3. “cognit* impair*”.ti,ab.
4. MCI.ti,ab.
5. AAMI.ti,ab.
6. ACMI.ti,ab.
7. ARCD.ti,ab.
8. CIND.ti,ab.
9. (nMCI or aMCI or mMCI or MCIa).ti,
ab.
10. “old* age*”.ti,ab.
11. elderly.ti,ab.
12. “middle age*”.ti,ab.
13. “old* adults”.ti,ab.
14. seniors.ti,ab.
Dec 2014: 202
Jul 2015: 15
Mar 2016: 10
Aug 2016: 0
Mar 2017: 14
Jan 2018: 9
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15. “senior citizens”.ti,ab.
16. “community dwelling”.ti,ab.
17. pensioners.ti,ab.
18. or/1-17
19. exp Cognition/
20. exp Dementia/
21. 19 or 20
22. randomi?ed.ti.
23. (randomly adj2 allocat*).ab.
24. (randomly adj2 divide*).ab.
25. RCT.ti,ab.
26. “double-blind*”.ti,ab.
27. “single blind*”.ti,ab.
28. “randomi?ed trial”.ab.
29. “randomi?ed control* trial”.ab.
30. “random allocation”.ab.
31. “controlled clinical trial”.ti,ab.
32. or/22-31
33. exp Vitamins/
34. exp Dietary Supplements/
35. vitamin*.ti,ab.
36. mineral*.ti,ab.
37. calcium.ti,ab.
38. Calcium/
39. exp Ascorbic Acid/
40. exp Folic Acid/
41. “folic acid”.ti,ab.
42. cholecalciferol.ti,ab.
43. ergocalciferol.ti,ab.
44. toxiferol.ti,ab.
45. retinol.ti,ab.
46. retinal.ti,ab.
47. “retinoic acid”.ti,ab.
48. “beta-carotene”.ti,ab.
49. “alpha-carotene”.ti,ab.
50. “gamma-carotene”.ti,ab.
51. “beta-cryptoanthin”.ti,ab.
52. thiamine.ti,ab.
53. riboflavin.ti,ab.
54. niacin.ti,ab.
55. nicotinamide.ti,ab.
56. pantothenic.ti,ab.
57. pyridoxine.ti,ab.
58. pyridoxal.ti,ab.
59. pyridoxamine.ti,ab.
60. biotin.ti,ab.
61. “folic acid”.ti,ab.
62. cyanocobalamin.ti,ab.
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63. methylcobalamin.ti,ab.
64. “l-ascorbic acid”.ti,ab.
65. “ascorbic acid”.ti,ab.
66. ascorbate.ti,ab.
67. phylloquinone.ti,ab.
68. phytomeadione.ti,ab.
69. phytonadine.ti,ab.
70. multivitamin*.ti,ab.
71. “diet* supplement*”.ti,ab.
72. iron.ti,ab.
73. zinc.ti,ab.
74. sodium.ti,ab.
75. potassium.ti,ab.
76. phosphorus.ti,ab.
77. magnesium.ti,ab.
78. chloride.ti,ab.
79. sulphur.ti,ab.
80. mangansese.ti,ab.
81. cobalt.ti,ab.
82. selenium.ti,ab.
83. copper.ti,ab.
84. iodine.ti,ab.
85. fluoride.ti,ab.
86. 18 or 21
87. or/33-85
88. 86 and 87
89. 32 and 88
90. exp *Vitamins/
91. (vitamin* or mineral*).ti.
92. 90 or 91
93. exp *Cognition/
94. (cognition or cognitive).ti.
95. 93 or 94
96. (elderly or “middle age*” or “old*
adults” or MCI or “mild cognitive impair-
ment”).ti
97. 92 and 95 and 96
98. (randomised or randomised or RCT or
trial).ti.
99. 97 and 98
100. 89 not 99
CINAHL (EBSCOhost)
(Date of most recent search: 25 January
2018)
S1 (MM “Vitamins+“)
S2 (MM “Minerals+”)
S3 (MH“Dietary Supplements”)OR (MH
“Dietary Supplementation”) OR (MH
“Dietary Carbohydrates”) OR (MH “Di-
etary Fiber”) OR (MH “Sodium, Dietary”)
OR (MH “Dietary Fats”) OR (MH “Di-
etary Proteins”) OR (MH “Dietary Su-
Dec 2014: 493
Jul 2015: 7
Mar 2016: 35
Aug 2016: 15
Mar 2017: 24
Jan 2018: 23
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crose”)
S4 TX vitamin*
S5 TX mineral*
S6 TX “diet* supple*”
S7 (MH ”Fatty Acids“) OR (MH ”Fatty
Acids, Omega-6“) OR (MH ”Fatty Acids,
Unsaturated“) OR (MH ”Trans Fatty
Acids“) OR (MH ”Fatty Acids, Monoun-
saturated“) OR (MH ”Fatty Acids, Satu-
rated“) OR (MH ”Fatty Acids, Essential”)
S8 TX “fatty acid*”
S9 (MH “Vitamin A”)
S10 (MH”Vitamin B12“) OR (MH”Vita-
min B Complex“) OR (MH ”Thiamine“)
OR (MH ”Riboflavin“) OR (MH ”Pyri-
doxine“) OR (MH “Carnitine”)
S11 (MH “Folic Acid”)
S12 (MH ”Ascorbic Acid”)
S13 (MH “Vitamin D”) OR (MH “Chole-
calciferol”) OR (MH “Ergocalciferols”)
OR (MH “Calcitriol“)
S14 (MH ”Vitamin E“) OR (MH ”Pan-
tothenic Acid”)
S15 (MH “Vitamin K”) OR (MH “Osteo-
calcin“)
S16 TX “beta-carotene”
S17 TX “alpha-carotene“
S18 TX thiamine
S19 TX riboflavin
S20 TX niacin
S21 TX pantothenic
S22 TX nicotinamide
S23 TX pyridoxine
S24 TX pyridoxal
S25 TX biotin
S26 (MH “Calcium”)
S27 TX calcium
S28 TX iron
S29 (MH “iron”)
S30 (MH “Zinc”)
S31 TX zinc
S32 (MH “Sodium”)
S33 TX sodium
S34 (MH “Potassium“)
S35 TX potassium
S36 (MH “Phosphorus”)
S37 TX phosphorus
S38 (MH “Magnesium“)
88Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
(Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
S39 TX magnesium
S40 (MH ”Sodium Chloride, Dietary”)
S41 TX chloride
S42 TX sulphur
S43 TX cobalt
S44 TX selenium
S45 TX copper
S46 TX iodine
S47 TX flouride
S48 S1 OR S2 OR S3 OR S4 OR S5 OR
S6 OR S7 OR S8 OR S9 OR S10 OR S11
OR S12OR S13OR S14OR S15OR S16
OR S17OR S18OR S19OR S20OR S21
OR S22OR S23OR S24OR S25OR S26
OR S27OR S28OR S29OR S30OR S31
OR S32OR S33OR S34OR S35OR S36
OR S37OR S38OR S39OR S40OR S41
OR S42OR S43OR S44OR S45OR S46
OR S47
S49 (MH “Aging“)
S50 (MH”Aged“)OR (MH”Aged, 80 and
Over”)
S51 (MH “Middle Age”)
S52 TX ”Mild Cognitive Impairment”
S53 TX MCI OR AAMI OR ACMI OR
ARCD OR CIND
S54 TX nMCI OR aMCI OR mMCI OR
MCIa
S55 TX elderly
S56 TX “old* adults”
S57 TX ”old* age*”
S58 TX pensioners
S59 TX “community dwelling”
S60 TX seniors
S61 TX ”senior citizen*”
S62 TX “age* sample”
S63 TX ”age* population”
S64 S49ORS50OR S51ORS52OR S53
OR S54OR S55OR S56OR S57OR S58
OR S59OR S60OR S61OR S62OR S63
S65 S48 AND S64
S66 (MH “Cognition”) OR (MH “Cogni-
tion Disorders”) OR (MH “Delirium, De-
mentia, Amnestic, Cognitive Disorders”)
S67 TX cognition
S68 TX memory
S69 (MH ”Memory“) OR (MH ”Mem-
ory Disorders“) OR (MH ”Memory, Short
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Term”)
S70 TX “executive function”
S71 TX ”cognitive* declin*”
S72 TX “cognitive* improv*”
S73 TX ”cognitive deficit*”
S74 TX “mental perform*”
S75 TX dementia
S76 TX alzheimer*
S77 (MH “Dementia+”)
S78 S66ORS67OR S68ORS69OR S70
OR S71OR S72OR S73OR S74OR S75
OR S76 OR S77
S79 S65 AND S78
S80 (MH “Randomized Controlled Tri-
als”)
S81 AB randomly
S82 AB placebo
S83 AB groups
S84 AB RCT
S85 TX ”double blind*”
S86 TX “single blind*”
S87 TX ”controlled clinical trial”
S88 TI randomised
S89 TI randomized
S90 S80ORS81OR S82ORS83OR S84
OR S85 OR S86 OR S87 OR S88
S91 S79 AND S90
ISI Web of Science (includes: Web of
Science (1945 - present); BIOSIS Pre-
views (1926 - present); MEDLINE (1950
- present); Journal Citation Reports); BIO-
SIS Previews
(Date of most recent search: 25 January
2018)
(“mild cognitive impairment” OR elderly
OR “age* subjects” OR “old* adult*” OR
“middle age*” OR MCI) AND TOPIC:
(“randomly allocated” OR “random alloca-
tion” OR randomised OR randomized OR
RCT OR “controlled trial” OR “double
blind” OR “single blind”) AND TOPIC:
(vitamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine) AND TOPIC: (cogni-
tion OR dementia ORmemory OR “exec-
utive function” OR alzheimer*)
Timespan: All years.
Search language = Auto
Dec 2014: 932
Jul 2015: 34
Mar 2016: 100
Aug 2016: 43
Mar 2017: 67
Jan 2018: 55
LILACS (BIREME)
(Date of most recent search: 25 January
2018)
cognition OR “mild cognitive impair-
ment” OR elderly OR “aged subjects” OR
“older adults” OR “middle aged” [Words]
and randomly OR randomised OR ran-
Dec 2014: 28
Jul 2015: 0
Mar 2016: 0
Aug 2016: 1
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domized OR RCT OR “controlled trial”
[Words] and vitamin OR vitamins OR
mineral OR minerals OR “fatty acid” OR
“folic acid” [Words]
Mar 2017: 0
Jan 2018: 0
CENTRAL (via CRSO)
(Date of most recent search: 25 January
2018)
#1 MeSH descriptor: [Aged, 80 and over]
explode all trees
#2 MeSH descriptor: [Aged] explode all
trees
#3 MeSH descriptor: [Middle Aged] ex-
plode all trees
#4 MeSH descriptor: [Mild Cognitive Im-
pairment] explode all trees
#5 “cognit* impair*” or MCI
#6 elderly
#7 “old* adults”
#8 “old* age*”
#9 “old* sample”
#10 senior citizens
#11 pensioners
#12 seniors
#13 #1 or #2 or #3 or #4 or #5 or #6 or #
7 or #8 or #9 or #10 or #11 or #12
#14 MeSH descriptor: [Cognition] ex-
plode all trees
#15MeSHdescriptor: [Dementia] explode
all trees
#16 cognit*
#17 memory
#18 “executive function*”
#19 processing
#20 “mental perform*”
#21 dement*
#22 alzheimer*
#23 #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22
#24 MeSH descriptor: [Vitamins] explode
all trees
#25 MeSH descriptor: [Minerals] explode
all trees
#26 vitamin*
#27 mineral*
#28 “ascorbic acid”
#29 “folic acid”
#30 MeSH descriptor: [Fatty Acids] ex-
plode all trees
#31 zinc or iron or calcium or sodium or
potassium or magnesium or cobalt or cop-
Dec 2014: 395
Jul 2015: 10
Mar 2016: 50
Aug 2016: 48
Mar 2017: 90
Jan 2018: 54
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per or selenium or iodine or flouride or
chloride
#32 “beta-carotene”
#33 “alpha-carotene”
#34 thiamine
#35 riboflavin
#36 niacin
#37 biotin
#38 pantothenic
#39 nicotinamide
#40 pyridoxal
#41 “diet* suppl*”
#42 #26 or #27 or #28 or #29 or #30 or #
31 or #32 or #33 or #34 or #35 or #36 or
#37 or #38 or #39 or #40 or #41
#43 #13 and #23 and #42
Clinicaltrials.gov (www.clinicaltrials.gov)
(Date of most recent search: 25 January
2018)
In Intervention studies: [intervention] vi-
tamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine AND [condition]: cog-
nition OR “mild cognitive impairment”
OR elderly OR “aged subjects” OR “older
adults” OR “middle aged”
Trial Status: all
Dec 2014: 147
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 6
Jan 2018: 8
ICTRP Search Portal (http:/
/apps.who.int/trialsearch) (includes: Aus-
tralian New Zealand Clinical Trials Reg-
istry; ClinicalTrials.gov; ISRCTN;Chinese
Clinical Trial Registry; Clinical Trials Reg-
istry - India; Clinical Research Informa-
tion Service - Republic of Korea; German
Clinical Trials Register; Iranian Registry
of Clinical Trials; Japan Primary Registries
Network; Pan African Clinical Trial Reg-
istry; Sri LankaClinical TrialsRegistry; The
Netherlands National Trial Register)
(Date of most recent search: 25 January
2018)
In Intervention studies: [intervention] vi-
tamin* OR mineral* OR “diet* suppl*”
OR “ascorbic acid” OR “folic acid” OR
iron OR calcium OR sodium OR zinc OR
potassium OR magnesium OR cobalt OR
copper OR iodine AND [condition]: cog-
nition OR “mild cognitive impairment”
OR elderly OR “aged subjects” OR “older
adults” OR “middle aged”
Trial Status: all
Dec 2014: 25
Jul 2015: 0
Mar 2016: 2
Aug 2016: 0
Mar 2017: 4
Jan 2018: 2
TOTAL before de-duplication Dec 2014: 5071
Jul 2015: 233
Mar 2016: 496
Aug 2016: 304
Mar 2017: 631
Jan 2018: 522
TOTAL: 7257
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TOTAL after de-duplication Dec 2014: 3451
Jul 2015: 200
Mar 2016: 399
Aug 2016: 208
Mar 2017: 522
Jan 2018: 431
TOTAL: 5211
TOTAL after first assessment by the Crowd and CDCIG information specialists Dec 2014: 448
Jul 2015: 81
Mar 2016: 70
Aug 2016: 45
Mar 2017: 43
Jan 2018: 38
TOTAL: 725
Appendix 3. Dietary intake and recommended daily intake of included vitamins and minerals
Vitamin or mineral Daily exposure estimate from food sources,
excluding supplements,
for men and women in the UK (mg)
(Gregory 1990)
Reference Nutrient Intake
(RNI) for adults (= the amount
of a nutrient that is enough to
ensure that the needs of nearly
all a group (97.5%) are being
met) set by UK Committee on
Medical Aspects of Food and
Nutrition Policy (COMA) in
1991
(Food Standards Agency 2003)
Supplementary doses used in
studies included in this review
(mg)
Mean 95%ile
Folic acid 0.26 0.49 0.20 0.4 - 5.0
Vitamin B6 2.0 3.9 1.4 (men), 1.2 (women) 20 - 50
Vitamin B12 0.0062 0.020 0.0015 0.4 - 1.0
Vitamin C 64 160 40 400
Vitamin E 8.5 (12.69 IU) 18 (26.87 IU) Requirement varies widely with
diet, no fixed level of intake
recommended. COMA con-
cluded that daily intakes of
4mg and 3mg of α-tocopherol
equivalents (5.97 IU and 4.48
330 - 2000 IU (International
Units)
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IU) could be adequate for men
and women respectively (Food
Standards Agency 2003)
Chromium 0.1 (source MAFF 1999) 0.17 COMA has set no RNI but
suggests intake above 0.025mg/
day is adequate for adults.
US National Research Council
specify an
Estmated Safe and
Adequate Daily Dietary Intake
(ESADDI) of 0.05-2.0mg/day
for adults
1.0
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, overall cognitive functioning was a secondary outcome. In the review, we have made it a primary outcome. This is
because studies were selected for inclusion if they reported either the incidence of dementia or a continuous cognitive function measure
at follow-up. It was an objective of the review, reflected in the title, to assess both of these as the key outcomes.
After the publication of the protocol, we added the exclusion of study populations with severe vitamin or mineral deficiency where the
intervention given could correct these deficiencies. However, we included studies of participants with mild vitamin deficiencies which
are common in the older population.
In the case of studies of B vitamins, we added baseline serum homocysteine level as a potential effect modifier and decided to report
effects in subgroups distinguished by baseline serum homocysteine.
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